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Abstract 
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the International Stem Cell Forum published a consensus on principles of best practice for the 
procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for 
research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) 
lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early 
seed stocks of stem cell lines intended for clinical applications. 
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Points to consider in the development of seed 
stocks of pluripotent stem cells for clinical 
applications: International Stem Cell Banking 
Initiative (ISCBI)
1. Background and utility of this 
document
In 2009 the International Stem Cell Banking 
Initiative (ISCBI) contributors and the Ethics 
Working Party of the International Stem Cell 
Forum published a consensus on principles of 
best practice for the procurement, cell banking, 
testing and distribution of human embryonic 
stem cell (hESC) lines for research purposes [1], 
which was broadly also applicable to human 
induced pluripotent stem cell (hiPSC) lines. 
Here, we revisit this guidance to consider what 
the requirements would be for delivery of the 
early seed stocks of stem cell lines intended for 
clinical applications. The term ‘seed stock’ is 
used here to describe those cryopreserved stocks 
of cells established early in the passage history 
of a pluripotent stem cell line in the lab that 
derived the line or a stem cell bank, hereafter 
called the ‘repository’. The seed stocks should 
provide cells with suitable documentation and 
provenance that would enable them to be taken 
forward for development in human therapeutic 
applications. WHO recommendations for the 
evaluation of animal cell cultures as substrates 
for the manufacture of biologicals and for the 
characterization of cell banks were updated in 
2010 and provide a number of definitions and 
guiding principles that may apply to stem cells. 
The term ‘cell bank’ is used to describe a stock of 
vials or other containers of cells with consistent 
composition aliquoted from a single pool of cells 
of the same culture history (for other specific 
definitions see PAS 84 [2] and WHO [3]).
Three important assumptions have been made 
in the preparation of this document. First, that 
seed stocks of hPSCs are used as starting mate-
rials to make cell banks for use in clinical tri-
als. The cell banks made within a clinical trial 
would need to be established according to Good 
Manufacturing Practice (GMP) in a facility with 
a relevant product manufacturing license. These 
banks would need additional risk assessment 
focused on the new banking process/reagents 
and the specific intended clinical application. 
Second, it has been assumed that undifferenti-
ated pluripotent stem cells would not be inocu-
lated into patients. Third, where feeder cells are 
used to culture hPSC lines, their cellular nature 
and intimate contact with the therapeutic cells 
means that they should be subject to similar risk 
assessment and banking procedures as applied to 
the hPSC cells. 
It is important to note that responsibility 
for establishing and updating national regula-
tions for medicinal products relies on National 
Regulatory Authorities. Therefore, national 
requirements for cell therapy may vary consid-
erably. Accordingly, it is not intended that this 
international consensus provides comprehen-
sive guidance that will ensure compliance with 
requirements in any given jurisdiction. Rather, 
it is designed to aid the development of clinical 
grade materials by providing points to consider 
in the preparation of seed stocks of stem cell lines 
for use in cell therapy. It may arise that there are 
circumstances where it is not reasonably pos-
sible to meet specific procedures presented in this 
document. Where this is the case any alterna-
tive procedures should be justified and mitigate 
against any adverse consequences. Finally, this 
document could also serve as a useful reference 
to assist in the evaluation of potential sources 
of candidate cell lines for the development of 
cell-based medicines, and provide the links nec-
essary to identify some of the key differences in 
re gulatory requirements between countries. 
2. Governance and ethics 
 2.1 General principles
Centers banking stem cell lines (hereafter called 
repositories) should adopt transparent and 
harmonized protocols for the collection, stor-
age, access, and use of the cell lines that they 
curate. As part of a comprehensive governance 
structure, repositories should establish robust 
mechanisms for the authentication of bone fide 
users and should strive for equitable and trans-
parent conditions of access and of material trans-
fer (Appendices 1a, 1b and 2). Such protocols 
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should be adopted according to internationally 
accepted principles for research ethics and in 
compliance with applicable legal, ethical and 
regulatory requirements (Appendix 3, 4 and 
5). Furthermore, repositories should establish 
a system for documenting and monitoring per-
formance with respect to such principles and 
requirements. 
 2.2 Key issues in determining 
provenance of pluripotent stem cell 
lines
Repositories should ascertain the provenance 
(source/origin) of the human biological speci-
mens from which the pluripotent stem cell lines 
have been derived. International guidance exists 
for documenting the provenance of the cell lines 
[1,4–7]. 
Important issues to consider when evaluating 
provenance include:
 Evidence of free and voluntary informed con-
sent, for the proposed research use, in con-
junction with independent review and over-
sight, with particular attention given to dis-
closure of potential clinical and commercial 
applications.
 The extent to which reimbursement (e.g., 
expenses, financial incentives, monetary pay-
ments) were provided for donation of biologi-
cal samples.
 The ability of the donor to withdraw original 
specimens, derived cell lines, data or otherwise 
to discontinue participation in research.
 The possibility that derived cell lines may be 
used for a wide range of research, possibly 
through a public repository.
 The establishment of robust systems for data 
security and traceability.
 The implementation of mechanisms for the 
protection of donor privacy and confidential-
ity. Particular attention should be given to the 
generation and use of genome sequence data. 
Many national and more local jurisdictions 
have explicit policies governing the acquisition 
and use of human biospecimens for pluripotent 
stem cell derivation, particularly with regard to 
embryonic sources (Appendix 3 and 4). Prior to 
accepting a pluripotent stem cell line, a reposi-
tory should determine its provenance by first 
documenting that the biospecimen was collected 
and the cell line derived in a manner broadly 
consistent with international standards for 
research ethics [4,5,6,7,201]; and second, to make a 
positive determination that the biospecimen was 
obtained in a manner consistent with applicable 
laws in the country of origin. 
2.2.1 Provenance determination and 
international standards
Providers of cells should be able to demonstrate 
to the repository that they have met all applicable 
legal and ethical requirements associated with 
the procurement of a human biospecimen from 
which a pluripotent stem cell line was derived. 
Given the heterogeneity of national laws and 
regulations governing research and clinical 
applications, the depositor of a cell line should 
provide information that enables the repository 
governance structure to determine whether the 
conditions of derivation, use and distribution are 
broadly consistent with the repository’s national 
regulation. Moreover, repositories should have 
in place a mechanism (e.g., ‘horizon scanning’, 
advisory board) to track changes in the legal 
and regulatory frameworks. In addition, reposi-
tories should verify and retain sufficient docu-
mentation to support a determination that each 
cell line has been obtained in accordance with 
i nternational standards for research ethics. 
Key principles include the following:
Independent review and oversight
The protocol for procurement of tissues, gametes 
or embryos for the purpose of generating a pluri-
potent stem cell line should be subject to inde-
pendent scientific and ethical review. Review 
bodies include ethics committees, licensing 
bodies or committees responsible for oversight 
of research involving human subjects.
Voluntary informed consent
In addition to verifying appropriate informed 
consent, the repository should ascertain addi-
tional details regarding donor’s disclosure 
when available (Appendix 1b). Numerous bod-
ies and national policies recommend or require 
the disclosure of specific information to donors 
(particularly for hESC derivation). A number 
of jurisdictions have consent requirements that 
include, but are not limited to, disclosure of possi-
ble human transplantation, genetic modification, 
international sharing and commercial potential. 
Documentation of a robust informed consent pro-
cess that addresses these requirements can serve 
to support wide distribution and utilization of the 
cell lines (Appendix 3 and 4). Informed consent 
requirements for stem cell derivation, use and 
banking have evolved over time and jurisdictional 
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variations may exist for different sources of bio-
specimens. In addition, standards for evaluating 
informed consent processes may need to be flex-
ible and allow for context-specific considerations. 
For example, agreement to banking could include 
broad consent to future unspecified research 
(subject to appropriate security mechanisms 
and governance); whereas some protocols may 
be intended to develop a specific cell product. 
Donors should be notified of the possibility of 
future use in cellular therapies, commercialization 
of eventual products and of the international shar-
ing of samples and of stem cell lines. Moreover, 
donors should also be informed of the limitations 
in privacy protection (see section 3.2 & 5.1) given 
the need to assure traceability for safety reasons 
(see section 6.9).
Gratuitous donation
Donors should not be paid to provide somatic 
cells, gametes or embryos for stem cell derivation, 
nor should they be reimbursed for any costs, such 
as tissue storage, prior to the d ecision to donate.
2.2.2 Compliance determination and 
access policies
Mechanisms should be in place to make a posi-
tive determination of compliance with both 
the ethical and legal requirements of the juris-
diction of biospecimen’s origin, together with 
those of the jurisdiction where the cell line was 
derived, deposited, and will be used in research 
(Appendix 3 and 4). Furthermore, it is impor-
tant to consider that there may be jurisdictional 
or funding agency restrictions on the types of 
cell lines eligible for research use as may be the 
case for hESC lines. To the extent feasible the 
repository should strive to compile complete 
provenance information for evaluation; however, 
it is ultimately incumbent on the end user of the 
cell line to determine that its provenance meets 
local ethics and legal requirements. 
Repositories should also adopt transparent, 
flexible and equitable access policies. Given the 
importance of international collaboration, such 
policies should include procedures for deposit of 
cell lines of foreign origin, and for the distribu-
tion of cell lines to researchers in other jurisdic-
tions. Among the policy criteria to be considered 
are the following:
 Mutual recognition via ‘reciprocal policy 
agreements’ allowing for transnational sharing 
of cell lines provided that the cell lines were 
derived by, or approved for use by, a licensing 
entity formally recognized as having adopted 
consistent ethical and legal requirements.
 ‘Substantial equivalency’ whereby criteria for 
cell line derivation, use, and banking in dif-
ferent jurisdictions involve ethical and legal 
requirements that are deemed to be ‘broadly’ 
or ‘substantially’ acceptable to the repository 
management and under applicable regulation.
3. Provenance and selection of donor 
tissue
 3.1 Donor selection, screening and 
medical records
Eligibility criteria for embryo, cell or tissue 
donors intended for human transplantation are 
subject to national regulatory frameworks and 
institutional protocols in the jurisdiction of ori-
gin. As a general rule, donor eligibility determi-
nation requires screening for risk factors associ-
ated with infection and communicable disease. 
These are typically focused on serum human 
viral blood-born pathogens (e.g., HIV, hepatitis 
B virus, hepatitis C virus) and may also include 
other pathogens endemic to the donor’s origin 
(e.g., human T-cell lymphotropic virus I&II, 
Chaga’s disease, malaria). Donor testing for 
these agents may be required to be carried out 
under national licensed facilities. 
For hESCs there are a number of consider-
ations pertaining to donor screening protocols 
for assisted reproduction treatment (Appendix 
4). For hiPSC evaluation, inclusion and exclu-
sion criteria represent a starting point for risk-
assessment or risk mitigation. In some cases, 
inclusion criteria may call for the collection 
of cells and tissues from patient groups with 
specif ic clinical (disease) indications. Any 
information regarding known disease indi-
cation should be associated with specific cell 
and tissue samples to support risk evaluation 
(see section 6.3). While cell lines derived from 
patients with inherited disease have been recog-
nized as having potential scientific utility, they 
are unlikely to be suitable for development of 
general clinical applications.  
Finally, regulatory authorities responsible 
for the evaluation of biological products con-
sistently emphasise the value of a donor medi-
cal history. It is important to note that rules 
adopted in some jurisdictions may require a 
review of donors’ relevant medical records 
and or a medical history screening; consider-
ations for extended medical histories have been 
p ublished by Murdoch et al. [8].
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 3.2 Allogeneic cell transplantation
The establishment of hiPSC repositories for 
human leukocyte antigen (HLA) haplotype rep-
resentation to facilitate immune-genetic match-
ing is a proposition already being pursued. Of 
particular interest are individuals who will be 
homozygous for common HLA haplotypes to 
maximise prospective histocompatibility match-
ing, although it is important to note that rejec-
tion will also be mediated by other non-HLA 
associated molecules. In the establishment of 
these resources, health screening, medical his-
tory and life style documentation will be impor-
tant sources of information the help assure the 
prospective patient safety as described below. 
However, defining what constitutes a a fully 
functional and ‘safe’ genetic state is more prob-
lematic and may not be resolved by development 
of autologous hiPSC lines as observed in mouse 
models. For hESCs derived from surplus IVF 
embryos, the risk of carrying genetic deficien-
cies has largely been presumed minimal. This is 
based on two presumptions: that the infertility 
of the donors is not in fact a congenital defi-
ciency, and that the culture and manipulation 
of embryos in vitro does not result in genetic 
and epigenetic perturbations. For hPSC lines 
in general, it is not possible to screen for cell 
inheritable genetic or epigenetic conditions that 
are not known, and these risks are thus tolerated 
(Advisory Committee on the Safety of Blood, 
Tissues and Organs [SaBTO] [9]). In the case 
of some homozygous HLA haplotypes there are 
also disease associations (see section 4.4). 
There is a reasonable prospect that in the near 
future there will be affordable access to personal-
ized genomic sequence information. If genomic 
sequence information of banked hiPSC lines 
were also made openly available to research, then 
anonymized, or de-identified, donors could ulti-
mately identify cell lines derived from them, or 
conversely be potentially identified by others [10]. 
Banking of hiPSC lines may, therefore, require 
greater attention to systems for preserving donor 
privacy [11].
 3.3 Ongoing donor traceability and 
management of post-donation disease 
and adverse events in patient 
treatment
Ideally, there should be a mechanism that allows 
a link to be made between cell line and donors, 
but only in exceptional circumstances such as 
seeking reconsent or to facilitate reporting of 
serious post-donation disease e.g., hepatitis C 
virus, variant Creutzfelt–Jakob Disease (CJD). 
While this should be considered, a risk–benefit 
analysis should also be carried out taking into 
account the administrative costs, together with 
ethical and policy considerations that such a 
system could impose. Of course, the repository 
should ensure that there is an effective tracking 
system for the cellular materials, from reception 
of tissue to the point of release to users to support 
internal troubleshooting and to enable manage-
ment of adverse events in clinical trials (section 
6.9). To this end, the donor’s informed consent 
should ideally allow for linkage to medical his-
tory and permission to re-contact. Linkage and 
re-contact will also raise, however, the possibil-
ity of donor(s) withdrawal (see section 2 and 
Appendices 3 & 4). 
In cases where the institution that creates the 
seed stock is a separate entity from the procure-
ment institution, the repository should retain 
sufficient records to allow traceability to the 
initial sample, while detailed information relat-
ing to procurement process and donor identity 
may remain with the organisation responsible 
for procurement (see section 6.8). 
 3.4 Advantageous capture of 
biological specimens 
In certain jurisdictions it is required that donor 
blood samples be associated with embryos 
intended for assisted reproductive treatments. 
Consequently, there may be blood or other bio-
logical specimens associated with some banked 
embryos and similar arrangements may be in 
place for some hiPSC lines. While such samples 
could inform future investigations, they are 
unlikely to have been consented for this purpose 
and retention of blood samples from embryo 
donors may not be the best archive material to 
use for the purpose of microbial safety testing. In 
fact samples from the cell line seed stock may be 
more appropriate for this purpose as proposed by 
Murdoch et al. [8]. For discussion on the consent 
issues relating to the use of archive tissues for the 
generation of hiPSC lines see Lomax et al. [12]. 
 3.5 Donor medical histories
In a number of jurisdictions a donor medical 
history may be required that identifies potential 
hazards in the past of the donor or their family 
and may also relate to aspects of the donor’s life-
style that may be associated with risk of infec-
tion. Repositories may wish to assure themselves 
that such information is accessible and even col-
late it in an anonymized, or de-identified, form 
(i.e., with donor name redacted); however, this 
may not be possible in some jurisdictions.
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If medical histories are not collected at the time 
of donation, re-contacting donors may be difficult 
or impossible if, for instance, they have changed 
location or have become deceased. When estab-
lishing requirements for collecting donor medical 
histories, it is important to decide what informa-
tion will be useful to collect [8].This will include 
risk factors such as sexual activity, drug abuse, 
cancer and family history of hereditary disease 
such as familial CJD. Finally, it is important to 
recognise that the management of donors may 
vary considerably in different jurisdictions, and 
in addition, the veracity of information provided 
by donors on certain risk factors may be difficult 
to determine. In conclusion, medical histories, 
in combination with donor virological testing, 
can be useful to screen out donated tissues carry-
ing higher risk of transmitting certain infections 
or other disorders, and thereby mitigate against 
certain risk factors. However, these alone do not 
necessarily assure safety of cell lines selected for 
use in clinical products, which will require supple-
mentary risk assessment and testing, as described 
in sections 4 and 5.  
 3.6 Disclosure of significant clinical 
information
In carrying out hPSC research, increasingly large 
genetic data sets are being generated. These will 
inevitably contain information on infectious 
disease and genetic inherited disorders that 
may be of relevance to the health of the donor 
and/or their relatives. The return of individual 
research results and incidental findings should 
be warranted and supported by informed donor 
consent, but also by protocols comprehensively 
detailing the nature of such findings, the mech-
anisms for disclosure and their management. 
Ideally, these procedures should be established 
prior to obtaining informed consent to donate. 
Moreover, such protocols should be transparent 
with regard to the conditions for such context-
specific and qualified disclosure [5].
 3.7 Withdrawal of bio-specimens 
and/or associated data
Obtaining medical information or other donor 
information on an ongoing basis constitutes 
human subjects research, and therefore, the par-
ticipant has the right to discontinue participation 
(research withdraw). The extent to which a par-
ticipant may withdraw will vary depending on 
the research protocol and applicable laws, but the 
withdrawal policy should be clearly described in 
the informed consent document. The following 
are common examples of w ithdrawal policies:
 Donors may request that donated embryos for 
hESC derivation, or somatic cells for hiPSC 
derivation, may be destroyed. However, it is 
generally accepted that derived hESC or 
hiPSC lines may continue to be used, and dis-
tributed materials cannot be recalled.
 Donors may request that all individually iden-
tifying information be removed from donated 
samples or resulting cell lines.
 Donors may request that further collection of 
medical information cease. Policies and legis-
lation vary with regard to the status of medical 
information already associated with a cell line.
 Donors may request to withdraw consent up to 
the time their tissue is used to derive a cell line. 
 Donors may request that they are no longer to 
be contacted by researchers.
Any or all of the above provisions may be 
applicable to a particular hESC or hiPSC line. 
Typically, donors are offered ‘staged’ withdrawal 
options where they may apply one or more of the 
options above, possibly at different time peri-
ods. It is important that the investigator or party 
responsible for interacting with the donor and 
the repository have clear procedures and proto-
cols in place to act upon withdrawal requests in 
a timely and effective manner.
4. Safety assessment of hPSC seed 
stocks
Whilst microbiological contamination is the most 
immediately evident hazard from cells intended 
for human therapy, there are a number of addi-
tional factors that should be considered. These 
include the presence of transformed cells, expres-
sion of potentially damaging bioactive molecules 
and the appearance of novel surface molecules 
following in vitro isolation and culture. The pres-
ence of potentially tumorigenic cells is clearly 
undesirable in a cell culture intended for clinical 
application. However, the remaining non-micro-
biological factors are more difficult to evaluate in 
terms of safety and more experience in the use 
of hPSC lines will be needed to assess the exact 
nature of any risk to patients.  This section con-
siders the primary biological issues for hPSC lines 
that will have a critical impact on their safe use 
in cell-based medicines, and considers approaches 
to reduce the risk of these hazards employing a 
risk-based approach.
It is obviously desirable that each stem cell 
line established for clinical use should be avail-
able for use in a broad range of therapies. The 
specific clinical settings and therapies to be 
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developed from these seed stocks are unlikely 
to be known and it is therefore not possible 
to carry out a full risk analysis that would be 
needed to determine the testing regime for a 
cell line used for a wide range of therapies. The 
testing regime required for release of cell banks 
will, therefore, inevitably be based on the likely 
generic hazards associated with cell culture and 
the specific hazards associated with the origin 
and specific culture history of each cell line on 
a case by case basis (see sections 4 & 6). All 
testing used for release of clinical grade seed 
stocks should be performed by a qualified and 
accredited laboratory according to national 
and/or international regulation and guidance. 
Similar standards should be applied to any cell 
banks of partially differentiated or feeder cells. 
It is recommended for a manufacturer using 
a cell line to produce a cell-derived biological 
product to focus testing and characterization on 
vials from the master cell bank (MCB) [3]. This 
practice can make testing regimes more efficient 
and ensures the MCB is fit, according to current 
best practice, for production of future working 
cell banks (WCBs). Additional testing of WCBs 
should be considered where justified based on 
science-based risk assessment, such as the risk 
of an expansion of a viral contaminant from 
culture reagents or a clonal expansion of karyo-
logically abnormal cells. However, developing 
guidance [3,14] proposes that alternative strategies 
may be justified, such as exhaustive testing of 
each working cell bank as it is produced. 
 4.1 Microbiological hazards 
4.1.1 General considerations on 
microbiological hazards 
A very broad range of microorganisms could 
potentially contaminate hPSC lines and some 
may be able to grow in cell culture becoming a 
permanent and non-cytopathic component of the 
cell culture. In addition, some of these organisms 
may have the capacity to transform human cells 
and present a tumorigenic hazard for clinical use 
[9]. The primary risk of contamination arises from 
the donor tissue used to generate the cell line and 
the associated most likely contaminants will, to 
some degree, be different for hPSC lines derived 
from embryos, where contamination from the 
reproductive tract may need to be considered, 
compared to hiPSC lines isolated from blood 
or skin cells. In addition, donor history (section 
2) and history of the cell line including storage 
conditions and detailed records of the reagents 
used (section  ), provide the key information to 
assess risk of contamination for each hPSC line. 
This risk assessment can then be used to estab-
lish the testing regime for the seed stocks of each 
cell line. Whilst virological testing of a donor is 
useful information in risk assessment, it does not 
guarantee freedom from viral contamination of a 
cell line derived from that donor’s tissue. Thus, in 
addition to risk mitigation (see section 6.2 & 6.3), 
microbiological testing of a cell line will provide 
c onfidence in its safety for use in humans. 
When cells are transferred from supplier to 
the manufacturer, a different set of conditions 
and reagents will apply and the appropriate test-
ing regime for MCBs and WCBs established for 
generating the cell therapy product, will need 
to be reassessed. Moreover, regulators are likely 
to expect fully qualified cell banks for manu-
facturing purposes, as recommended for banks 
of cells used in other aspects of manufacturing 
[3,13]. With this in mind some stem cell line 
repositories may choose to perform testing on 
seed stock cell banks only for the most serious 
potential contaminants, whilst others may carry 
out a borader range of testing on their cells.
Highly sensitive molecular and cell culture 
based assays have been established and qualified 
for the evaluation of cells used in the manufacture 
of vaccines and biotherapeutics [3,13]. However, 
it is important to recognise that current quali-
fied methods are not sufficiently broad ranging 
to provide an absolute guarantee of absence of 
microbial contamination. Deep sequencing tech-
nologies and microarray technologies [14–16] offer 
significant potential advances in the detection of 
virtually any agent in cell cultures, as has been 
demonstrated in cells used for vaccine manufac-
ture [17,18]. However, they have yet to be proven 
and validated for use with cell banks for clinical 
use. Repositories should keep a ‘watching brief ’ 
on emerging technologies and engage with their 
developer to assemble and analyze data that may 
be useful for clinical validation. Currently, such 
novel techniques lack appropriate validation for 
detection of different types of agents. It will be 
necessary to have widely available control materi-
als and procedures to manage unqualified data as 
developed by WHO for sequencing [19], and by 
the Minimum Information About a Microarray 
Experiment (MAIME) workgroup [20]) to provide 
minimal datasets from m icroarrays for interpret-
ing and a ssessing reproducibility of experiments. 
4.1.2 Microbiological testing
The following sections discuss the typical micro-
biological tests that should be considered for seed 
stocks of hPSC lines intended for clinical use 
and an example of a possible core testing regime 
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for a seed stock of hPSC is provided in Appendix 
6 (of note, this is a guide only to key issues and 
each repository must take responsibility for risk 
assessment and the final testing regime). ‘Next 
Generation Sequencing’ (NGS) offers power-
ful methodologies for the identification of any 
contaminant including organisms unknown to 
science. However, care is required in interpret-
ing data as widely available control materials 
and qualification data are yet to be established. 
Accordingly, the real value of a negative or a 
positive result may be uncertain. However, it has 
proved useful to pick up positive signals which 
must be verified by standardized and established 
techniques.   
Virological testing
Current established testing regimes do not 
enable routine release assays for detection of 
all known viral agents, and a risk assessment 
should be performed to ensure that tests for the 
most likely contaminants are applied based on 
risk associated with the origin and culture his-
tory of the cell line (see section 6.8). As already 
described, the more complete the documentation 
for the culture history of the hPSC line, the more 
robust the risk assessment can be and this in turn 
reduces the dependency on the cell bank safety 
testing regime. 
The risk of contamination of cell therapies 
by abnormal prion protein can be mitigated by: 
 Ensuring that any potentially contaminated 
culture reagents are traceable to low risk 
source materials.
 Sequencing of the associated prion gene to 
identify any cell types with mutations more 
susceptible to conversion to the abnormal 
state. 
 Testing regimes for particular abnormal pro-
teins of concern.
 Demonstrating failure of prion agents to sur-
vive and multiply in cell lines selected for 
development of cell therapies. 
The WHO has published suitable risk assess-
ment procedures to enable selection of source 
tissue of low risk [21], and this has been reflected 
in European guidance [22,23]. 
Repositories should ensure they have access 
to expert microbiological advice, usually in the 
form of an expert advisory group, which provides 
assistance in establishing local testing regimes. 
It is also beneficial for repositories to coordinate 
such activities to enable them to keep abreast 
of developments in emerging diseases and 
experience with contamination. It is important 
for banks to evaluate the risks associated with 
reagents (e.g., growth factors; see section 6.3) 
and ensure the appropriate sourcing of compo-
nents of lowest microbiological risk – especially 
for reagents such as serum and trypsin, where 
the reagent cannot be sterilized.
Sterility testing
Standard methods for sterility testing are pub-
lished by national authorities including the United 
States Pharmacopeia (USP), and the European 
Pharmacopeia (EP). Each repository should 
comply with its own national pharmacopoeia. 
However, these protocols are aimed to detect 
breaches in aseptic processing and typically do 
not use culture conditions that would enable isola-
tion of some more fastidious organisms that could 
proliferate in the complex media and conditions 
of cell culture. Additional detection methods may 
need to be considered to detect such organisms 
where they are considered to be a special hazard 
in the local environment or particular reagents. It 
is important to emphasise that antibiotics should 
not be used in culture media before sterility or 
mycoplasma testing is performed. In addition, 
antibiotics and antifungal agents should not be 
used in preparation of cells intended for therapy. 
Mycoplasma testing
Standard methods based on Vero cell inocula-
tion/DNA stain and culture isolation methods 
are published in USP, EP and other pharmaco-
peia. Polymerase chain reaction (PCR) meth-
ods are published and certain assay systems are 
accepted by the European Pharmacopeia but are 
not necessarily represented in all national phar-
macopeia [24,25].
Nested PCR may give greater sensitivity of 
detection, however, it can also give rise to false 
negatives. Direct quantitative PCR (qPCR) 
applied to inoculated mycoplasma broths may 
provide significant advantages regarding sensi-
tivity. Whichever method is selected, as for all 
analytical methods it will need to be qualified, 
and in routine testing working reference mate-
rials should be established (e.g. DNA prepara-
tions, quantified suspensions of organisms) to 
monitor sensitivity of testing over time.
 Genetic stability
4.2.1 General considerations on genetic 
stability 
Genetic changes that are known to occur in 
cultured hPSC lines [26– 28] could have a num-
ber of deleterious effects including loss of 
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functional characteristics and transformation 
into a tumorigenic state [29,30]. Cell lines in cul-
ture are known to be karyologically variable, 
and even human diploid fibroblasts, noted for 
their karyological stability, show subtle muta-
tions when analysed by single nucleotide poly-
morphism (SNP) arrays [31–36]. Non-diploid 
karyotypes are sometimes seen in apparently 
‘normal’ tissues. While the significance of such 
karyologically abnormal cells in vitro is yet to 
be determined they are considered a potentially 
serious issue for cells intended for implantation 
into humans. SNP variation in non-pluripo-
tent cells such as fibroblasts, mentioned above, 
could identify a baseline for genetic stability, 
but such base-lines may well vary with cell type 
and culture conditions. 
The degree of genetic stability of cultured 
cell lines intended for cell therapy should be 
a consideration in their selection, however, as 
already indicated, no cell line is likely to be 
absolutely stable in its genetic make-up when 
passaged in vitro. Risk associated with genetic 
instability can be minimized by limiting the 
time and number of passages in vitro (of note, 
cumulative population doublings should be used 
if these can be determined), and risk assessments 
should include consideration of the influence of 
any changes or variation in culture conditions. 
It has been clearly demonstrated that genetic 
changes occur in the early phase of hiPSC line 
derivation [37,38] and such changes may give a 
selective advantage for in vitro culture [39,40]. 
Selection of methods of hPSC line isolation that 
minimize the risk of such changes should be a 
significant consideration in cell line develop-
ment and selection of hPSC lines to be banked 
for  clinical application.
There is also evidence that culture conditions 
and passaging methods can dramatically influ-
ence the genetic stability of stem cells, even over 
relatively short culture periods [40,41]. Accordingly, 
a means of monitoring genomic stability is impor-
tant for cell bank testing. Karyotyping by Geimsa 
banding is the technique most commonly per-
formed, as this can identify changes in chromo-
somal numbers as well as translocations and other 
rearrangements. Demonstration of maintenance 
of a diploid karyotype at a certain passage number 
(e.g., every ten passages or equivalent population 
doublings) will be of value. Array comparative 
genomic hybridization is now increasingly used 
in clinical diagnosis and offers significant ben-
efits in terms of the size of genetic lesions that 
can be detected, although it will not recognise 
some aberrations such as balanced translocations. 
Other genomic information derived from tech-
niques, such as chromosome painting to identify 
aberrant chromosomes (e.g., spectral karyotyp-
ing, fluorescent in situ hybridization [FISH]) and 
deep sequencing can also be considered [42–46], 
however the sensitivity of these methods should 
be evaluated alongside the level of resolution of 
genetic changes and the availability of suitable 
controls. Analysis of wide ranging gene expres-
sion profiles has also been proposed as a means 
of virtual karyotyping and detection of genetic 
instability [47]. 
It may be useful to perform copy number anal-
ysis of certain sequences since there is evidence 
that specific lesions (deletions and duplications) 
are found repeatedly at specific genomic regions 
[47]. Copy number analysis can be performed 
using SNP or comparative genomic hybridization 
microarray analysis, as well as sequencing across 
the region of interest. However, the biological 
significance of gain or loss of small regions of the 
genome remains to be defined and such changes 
may arise in the donor population [37].
The epigenetic status of undifferentiated 
pluripotent stem cell lines has been widely 
investigated, but it is currently difficult to set 
standards for stem cells [48,49]. DNA methyla-
tion studies have not yielded clear and consis-
tent results with respect to stability. However, 
it is known that culture conditions can strongly 
influence DNA methylation [50–53]. Microarrays 
now allow affordable high-resolution genome-
wide DNA methylation analysis [52]. In the case 
of hiPSCs created from somatic cells, DNA 
methylation patterns might be an approach to 
determine whether cells have been completely 
reprogrammed from parental lines. For a review 
of epigenetic instability in hPSC lines see [26].
As part of the evaluation of a stem cell line for 
its suitability to deliver cell therapies, it will also 
be helpful to demonstrate that it is possible to 
passage the cell line up to or beyond the number 
of population doublings under conditions which 
replicate or simulate the actual production culture 
expansion process. Such qualification and test-
ing (e.g., phenotype, ultrastructure, virology) is 
prescribed by the WHO for cell substrates used 
for the manufacture of therapeutics and vaccines, 
which also considered the potential requirements 
for evaluation of stem cell lines for use in humans 
[3] (see also section 8.1).
4.2.2 Genetic stability testing
The requirement for karyological testing of seed 
stock may differ from the requirements for final 
product cells used in the manufacturing process. 
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The requirement for karyological analysis of seed 
stocks will depend on the characteristics of the 
cell line in question (e.g., its degree of genetic 
stability). It is considered sufficient for seed 
stocks that data on 20 Geimsa–banded meta-
phase spreads be provided and to have chromo-
some counts on a further ten metaphase spreads, 
as proposed for research grade cell lines [1]. This 
will enable the detection of karyologically abnor-
mal cells at the level of 5%, although certain 
abnormalities may not be detected. 
Certain levels of genetic abnormality may 
be acceptable in undifferentiated seed stocks, 
provided there are procedures that eliminate 
abnormal cells or any related hazard in cells for 
final clinical use. The recommended criteria for 
karyological screening of seed stocks is given in 
Table 1. However, cells to be used in cell therapy 
products will need to be evaluated on a case by 
case basis with respect to the karyotype. 
Whilst karyology is the current reference 
method for evaluating genome integrity, it may 
not be sensitive to small genetic changes. A 
number of important new techniques for char-
acterising the genome include spectral karyotyp-
ing, comparative genome hybridization (CGH) 
microarray, SNP microarrays, and whole genome 
sequencing. These offer the opportunity to ana-
lyze and understand changes in the genome at 
different levels of resolution. While these are still 
essentially research tools, CGH microarray is 
now becoming qualified for diagnosis of genetic 
disorders [54] and could be the first of these tech-
niques used for lot release by stem cell repositories. 
However, it should be noted that this technique 
does not detect balanced translocations and it is 
best practice that any genetic aberration detected, 
is validated using FISH. In general, these tech-
niques could benefit the characterization of stem 
cell lines intended for clinical use, but would be 
for ‘information only’ rather than release criteria. 
A better understanding of the levels and 
types of genetic instability of each type of cell 
culture and the potential impact on safety of 
the final product will clearly be important but 
is still developing. Repositories of stem cell lines 
should keep abreast of current developments 
e.g. through recruitment of appropriate experts 
for their advisory board. 
 4.3 Tumorigencicity versus 
pluripotency
General considerations on evaluation of 
tumorigenicity
The inoculation of cells into an immune-com-
promised host animal has been used for many 
years to evaluate the ability of different cell 
types to form or cause tumors as an indication 
of potential risk associated with the use of such 
cells to make therapeutic products and vaccines. 
Animal cells have been considered to have two 
types of capability to cause malignancy: first, 
tumorigenicity, by which the cells grow in a 
host organism in an uncontrolled way to cre-
ate masses of cells; and second, oncogenicity, by 
which cells or the components of cells are able to 
induce malignant growth of the host organisms 
cells. Clear definitions for tumorigenicity and 
oncogenicity have been established for such test-
ing in cells used for manufacture of products [3] 
and also proposed for use in cell therapy [2]. The 
same types of test methods are also used to assess 
the potential pluripotency of stem cell lines and 
some methodologies have been proposed as stan-
dards for assessing this property of hPSC lines 
[55]. The reproducibility and standardization of 
assays has been debated for many years [56], but if 
they are to be used it is important for the inves-
tigator to be absolutely clear on the objective of 
the test and standardized methodology for the 
intended purpose (tumorigenicity, oncogenicity 
or pluripotency), and to have clear criteria for 
assessment of the results. Of course, it should not 
be forgotten that the utility of teratoma forma-
tion from hPSC lines in mice is not just in the 
assessment of tumorigenicity, but also in provid-
ing potentially valuable tools for investigation of 
early human development [57]. 
4.3.1 Tumorigenicity testing
As for pluripotency testing (below), there has 
been tremendous variation in assays for in vivo 
tumorigenicty testing. The minimum inoculum 
dose is not standardized, but in many protocols 
106–107 cells are injected, in clusters, per animal. 
It is believed that the preparation of the cells and 
the site of inoculation could have a significant 
influence on results [58,59]. The strain of mouse 
could also influence the outcome of tumorige-
nicity assays due to differences in physiology 
and immune status. In the ISCBI survey (see 
Appendix 9) seven different strains of immune-
deficient mice were reported in use, some of 
which retain certain immune cell functions. 
For tumorigenicity testing mouse strains with 
multiple immune deficiencies, including lack of 
functional T- and B-lymphocytes and NK cells 
are recommended, including NOG (NOD/Shi-
scid/IL2Rgnull) [60,61] and also the NGS [263]. In 
addition, the time period of observation of inoc-
ulated animal and its predisposition to develop 
spontaneous tumors may also affect results of 
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tumorigenicity assays. A standardized method 
was recently published by the WHO for evalu-
ation of tumorigenicity in cells used for vaccine 
and biotherapeutic manufacture [3], but what-
ever method is used it will need to be optimized 
for detection of tumorigenicitiy in pluripotent 
stem cell lines. 
The role of assays specified to optimise detec-
tion of potentially malignant tumorigenic cells 
has not yet been established for hPSC lines. 
Teratoma assays established to evaluate plu-
ripotent potential of a culture are not designed 
to detect low levels of transformed malignant 
cells. However, the possibility to detect such 
cells present at a significant level in in vivo 
pluripotency assays should be born in mind 
when reviewing teratoma assay data. For in vivo 
tumorigenicity testing it will be important for 
such analysis to be performed by a qualified 
histologist familiar with the morphologies of 
teratoma (benign) and teratocarcinoma (malig-
nant) cytology and tumor formation. In addi-
tion, as prescribed for general good cell culture 
practice (GCCP) [63], it may also be valuable to 
carry out routine microscopical screening of 
cultures for abnormal cells. 
Table 1. Standard methods, procedures and recommended terms for the reporting of the karyological analysis 
of undifferentiated human pluripotent stem cells.
Karyological analysis of pluripotent stem cells
Standard Geimsa-band analysis Examination of  metaphases with eight metaphases analyzed (minimum) and 20 
metaphases counted (ISCBI, 2009)
Clonal abnormal findings Confirmation of clonal chromosome abnormalities in a later cell culture passage or 
calculated population doublings  
Abnormalities observed in single cells Aneuploidy of chromosomes 
Aneuploidy of chromosomes can be observed in pluripotent cell lines with most common 
occurrence for chromosomes 1,8,12,14,17 and X 
Analysis of a minimum of 30 G-banded cells counted from initial culture (ISCBI, 2009)
Follow-up analysis of a further 30 G-banded cells taken from a later passage cell culture 
in combination with the examination of 100 interphases using fluorescent in situ 
hybridization (FISH) with a relevant probe
Other aneuploidy and structural abnormalities
Analysis of a minimum of 30 G-banded cells counted from initial culture
Minimum quality score Minimal level of G-banding analysis for hESC lines for research purposes was published 
previously (ISCBI, 2009) and was developed from the International System for Human 
Cytogenetic Nomenclature (ISCN) in which analysis to Band level 400 was recommended 
with an expectation that analysis of band level 500 or above would be attempted
See also Professional Guidelines for Clinical Cytogenetics General Best Practice Guidelines 
(2007) v1.04 March 2007
Sub-standard analysis Failure to attain an ISCN 400 level of banding can be reported with the proviso that the 
analysis may need to be repeated
Reporting the results The report should contain:
The karyotype description stated using the current ISCN nomenclature 2009
The type of analysis used e.g., fluorescent in situ hybridization, type of banding
The average banding level attained
Single cells displaying aneuploidy or structural anomalies should be reported. Cells should 
be analyzed again after extended passaging (or high population doublings) in culture to 
investigate and interpret the abnormality
Definition of terms (taken from the Association 
for Clinical Cytogenetics Professional 
Guidelines for Clinical Cytogenetics, General 
Best Practice Guidelines [2007] v1.04)
Analyze: To count a metaphase and compare every chromosome, band for band, with 
its homologue and to verify the banding pattern of the X and Y-chromosomes in male 
karyotypes.
Clone: A cell population originally derived from a single progenitor cell. Such cells will 
have an identical chromosome constitution. Generally, in cytogenetics, a clone is said to 
exist if three cells have lost the same chromosome, or two cells contain the same extra or 
rearranged chromosome.
Count: To enumerate the total number of chromosomes in any given metaphase, or in 
FISH analysis to enumerate the number of signals in an interphase nucleus.
Examine: To look for the presence or absence of any abnormality in a case.
Score/screen: To check for the presence or absence of abnormalities in a cell or 
metaphase without full analysis.
Adapted from [1].
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Specially designed tumorigenicity assays that 
can detect low levels of tumorigenic cells, will 
also be important for cell therapy products [64,65]; 
however, this is out of the scope of the current 
document. 
 4.4 Genetic disorders
4.4.1 General considerations on inherited 
genetic disorders 
The genomes of any donor of tissue for genera-
tion of hPSCs, will contain sequences that are 
associated with predisposition to disease. How-
ever, it is relatively rare that such sequences 
become expressed in the individual’s phenotype, 
or otherwise develop (such as disease associated 
with expansion of DNA microsatellite repeats), 
and cause disease in the individual carrying the 
affected sequence. In addition, certain HLA 
allele haplotypes have autoimmune disease asso-
ciations (e.g., diabetes, multiple sclerosis, sys-
temic lupus erythematosus, rheumatoid arthri-
tis, celiac disease), but obviously donors with the 
disease-associated HLA alleles do not necessarily 
develop disease. 
The detection of a genetic attribute or varia-
tion in a donor is likely to mean that this is pres-
ent in the stem cell line. However, as already 
mentioned, pluripotent stem cell lines are known 
to acquire genetic and epigenetic changes during 
derivation and culture, thus, they may have more 
potential abnormalities than may be found in the 
donor. The real level of risk from these or other 
identified disease associated genetic variants to 
the functionality of cell therapies is uncertain. 
A possible exception to this may be where tumor 
suppressor genes, oncogenes or miRNA genes 
are altered or overexpressed, rendering the host 
cell potentially tumorigenic [66]. This obviously 
would need to be considered in safety assessment 
of the cellular products intended for therapy.
4.4.2 Genetic screening for disease-
associated sequences 
As discussed above and in section 3, the final 
impact of a genetic or epigenetic lesion in the 
donor in most cases will be unknown and test-
ing for disease associated genetic variations will 
generally not be helpful, unless the donor comes 
from a genetic line or population that suffers 
from a genetically inherited trait [9]. Current 
experience in therapeutic transmission of dis-
ease predisposition is currently limited to cell 
and tissue transplantation, predominantly from 
one donor to one recipient. Future experience 
with single cell lines developed for many patients 
will be needed to identify any real genetic risk 
factors. However, as also briefly discussed in 
section 3, it may be useful to screen for altered 
genes (oncogenes, growth factors, etc.) in cell 
lines. The Center for iPS Research and Applica-
tion (CiRA) Institute in Kyoto has published a 
list of oncogenes as a basis for such screening of 
hPSC lines, and microarray technology provides 
the means to do this routinely. Whole genome 
sequencing of cell lines intended for clinical use 
is generally agreed to be desirable to develop our 
scientific understanding of these cell types and 
repositories should seek to develop such data. 
However, given the issues of potential for donor 
identification (see above), repositories should 
establish policies and procedures for release of 
such data, that will oblige recipients of repository 
data to use it in a way that would not increase 
risk of donor identification [11]. Furthermore, 
in order to avoid presenting misleading data 
on cells for clinical use, repositories should also 
seek to assure that best practice has been applied 
in developing any genetic data they publicise. 
In particular, whole genome sequencing still 
requires development of appropriate standard-
ization, without which the data should be con-
sidered to be research data for information only 
and not necessarily relevant at this stage to estab-
lish suitability of lines for clinical application. 
5. Characterization of hPSC seed 
stocks
 5.1 Cell identity
It is part of GCCP [63] to authenticate cell lines. 
Cell line authentication is a critical step in the 
banking process, assuring that a cell line is not 
cross-contaminated by another line or otherwise 
misidentified. Methodologies for individual 
specific genetic identification have been stan-
dardized within the field of forensics, and com-
mercial services and kits are readily accessible 
as described in the guidance on research grade 
cells [1]. These kits typically comprise primers for 
up to 16 short tandem repeat (STR) DNA alleles 
with 5 or more of these alleles in common which 
can be utilized to facilitate direct comparison of 
cell line profiles even when generated by differ-
ent repositories using different kits (see [1] for a 
comparison of STR alleles shared between com-
mercial kits). Such comparisons are not so read-
ily achieved using other genetic identity testing 
techniques such as SNP analysis. It is advised 
that the STR testing be performed in accor-
dance with the Authentication of Human Cell 
Lines standard ANSI/ATCC ASN-0002–2011 
[67,201]. This standard advises the use of 8 STR 
loci with a match threshold of 80% to ensure 
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specific identification of the line. Reporting of 
DNA profile data should be considered carefully 
as donors could be identified [11,68].
In the case of multiple cell lines isolated from 
the same embryo or donor tissue, DNA finger-
printing is not likely to discriminate between 
such cell lines. It is important that such clones 
are identified clearly in their naming [69]. How-
ever, some means of demonstrating their unique 
identity will be required and if this is not pos-
sible by molecular analysis the mechanisms 
used to ensure the physical isolation of cell lines 
during culture should manage the risk of lines 
that have the same identity profile, becoming 
switched (see section 6.4). 
 Viability and measurement of 
growth
Special care should be given to choosing the time 
point at which viability tests are performed, as 
tests taken immediately after thawing may over-
estimate viability. It is therefore important for the 
repository to gain experience in assessing post-
thaw viability and survival of colonies under its 
own culture conditions. Regulators and others 
have addressed the idea of setting acceptability 
limits for viability, but this has proven difficult as 
it may be process and cell type-dependent. A range 
of other tests such as propidium iodide, neutral 
red assay, fluorescein diacetate or alamar blue may 
be used, but each give data on a different aspect of 
cellular fiunction. Other regulatory guidance on 
cell substrates used for manufacturing purposes 
[3], councils that the method of viability testing, 
and the levels of viability considered acceptable, 
should be established based on their suitability for 
the specific cell types in question and scientific 
knowledge of the cell type. This latter position 
is especially relevant for stem cell lines. Finally, 
it is important to recognise that viability does 
not necessarily predict desired functionality of a 
cell preparation, which must be demonstrated by 
other means (see section 5.3 & 5.4). 
The nature of growth measurements will 
depend on whether cells are passaged as single 
cell suspensions or colony fragments. Single 
cell suspension passage is the more convenient 
and more efficient technique, but will require 
validation in each laboratory to assure that the 
genetic stability and pluripotent potential of the 
stem cell lines is not affected. Growth rate is an 
important characteristic that needs to be moni-
tored using population doublings where possible, 
as an increase in cell replication rate may indi-
cate transformation. Switching growth medium 
may affect growth rate, but this would typically 
be reversible on return to original medium, if 
the cells have not become transformed or per-
manently altered in some other way. Alkaline 
phosphatase-positive colony-forming assays may 
also be useful for quantitation of growth of stem 
cell lines [70].
 5.3 Characterization  of gene and 
antigen expression 
Characterization  of gene and antigen expression 
provides useful fundamental information on cell 
state and the variability and consistency of cul-
tures, especially where assays allow many targets 
to be evaluated simultaneously as in microarrays 
(e.g., whole genome expression arrays [Illumina, 
Agilent or Affymetrix], TaqManTM Low Density 
Array cards, ScorecardTM [LifeTechnologies]) 
and the multi-flourochrome labelling of cells. 
There are a range of antibody-based markers that 
are used for identification of different stem cell 
types [71] and further markers may be useful to 
qualify the nature and state of pluripotent stem 
cells [72]. 
It is well known that pluripotent stem cell 
cultures vary in gene and antigen expression 
from one passage to another [73], but a stem cell 
repository should seek to set acceptable ranges 
for expression in the culture systems they use. 
Typical surface antigen markers that may be 
used to monitor phenotypic stability are indi-
cated in Appendix 6. Control cell cultures are 
useful to run in parallel with undifferentiated 
cell lines and in number of settings the 2102Ep 
embryonal carcinoma cell line has been rec-
ommended for this purpose as it shows stable 
expression of common hPSC markers [73–75]. 
However, pluripotency assays have greater value 
in that they provide an indication that the rel-
evant functional capabilities of a pluripotent 
stem cell line remain unaffected by the b anking 
process (Appendix 6).
To assure the quality of reprogrammed cells 
it is important to demonstrate that expression 
of exogenous reprogramming factors has been 
silenced or removed. In retroviral systems, that 
are unlikely to be used in cells for clinical appli-
cation, incomplete silencing is an indicator of 
partial reprogramming and checks for sustained 
silencing of exogenous factors may be needed 
with less optimal vector systems. For non-inte-
grating reprogramming vectors, which in theory 
are the most promising for clinical applications 
[76,77], it is important to demonstrate silencing 
and removal of the original exogenous expression 
system (episomal viral construct or mRNA). 
Accordingly, both antibody- and qPCR-based 
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test methods are available for the commercially 
available regprograming kits and qualification of 
the sensitivity of these methods would be needed 
if iPSC for lines were to be considered for clini-
cal applications. It should be born in mind that 
non-integrating virus constructs may persist for 
a number of passages and testing is typically 
performed between passage 5–10 after an iPSC 
line has been established (see also Appendix 6). 
 5.4 Pluripotency assays
5.4.1 General considerations on 
pluripotency
Teratoma assays to evaluate the pluripotency of 
stem cell lines provide a valuable characterization 
of the key functional feature of these cells (i.e., the 
benign tumors exhibit tissue representing all three 
germ layers required to form the human body). 
However, responses to a survey by the Interna-
tional Stem Cell Initiative (ISCI; see Appendix 9 
for details) and other reports [79] have revealed sig-
nificant variation in methodologies used to per-
form the teratoma assay, which might be expected 
to influence the ability to compare data from dif-
ferent Centers directly. The range of parameters 
that may affect the reliability of teratoma data, 
including the strain of mouse used, are consistent 
with those which may influence tumorigenicity 
assays as discussed in section 4.3.2. An approach 
to develop a standardized tumorigenicity assay 
has been proposed by Gropp et al. [55]. 
A number of papers have been published [78–
80] proposing assays using a transcriptome-based 
bioinformatic approach. Alternative ways of ana-
lysing the pluripotent properties of cells is an 
active area of investigation, and methods includ-
ing gene expression profiling of differentiating 
cells in vitro in embryoid bodies or earlier phases 
of induced differentiation, or the analysis of epi-
genetic status [52,81,82] are being considered. Plu-
ripotency can also be characterized by formation 
of embryoid bodies in vitro and gene expression 
or immunological marking of the three germ lay-
ers, or use of directed differentiation protocols. 
These are also being used in combination with 
gene expression systems to provide assays that 
could replace the use of teratomas [56]. 
5.4.2 Pluripotency testing
Pluripotency assays can be used to give an indi-
cation that the cell line has not been altered by 
in vitro culture, although it should be recog-
nised that they are not conclusive for pluripo-
tency in this respect (i.e., demonstrate the cell 
lines capability to generate all cells of the adult 
human body or that the cell retains normal 
differentiation pathways). Testing using one or 
a combination of assays for pluripotent potential 
qualified by the stem cell repository (see Appen-
dix 6) may, therefore, give an indication that 
the cell line has not been affected by its deriva-
tion and culture history and retains a potentially 
broad range of capability for cell therapy.  Con-
versely, it may be concluded that a purported 
pluripotent cell line that fails to demonstrate 
potential pluripotency may have been isolated 
from cells that were not fully pluripotent or has 
undergone deleterious changes during isola-
tion and culture. For this reason, and also to 
assure broad potential applicability in therapy, 
it is therefore recommended that stem cell lines 
should be assessed for pluripotency. 
At this time it is not possible to make firm 
conclusions about the most suitable methods 
to use as a pluripotency assay for seed stocks 
intended for clinical use. Stem cell line reposi-
tories will need to consider what method is most 
appropriate to confirm the desired characteris-
tics of the cells they release. Ideally, more than 
one assay type would be used, that in combi-
nation reveal different aspects of pluripotency, 
that is, the ability to show molecular evidence 
for the ability to commit to all three germ line 
lineages, but also to create cells representative 
of certain tissue phenotypes typical of the three 
germ lineages. 
6. Regulation and quality assurance
 Quality assurance: general principles 
Stem cell repositories providing cells intended 
for use in humans require an established quality 
assurance (QA) procedure providing a formal 
methodology and due diligence, designed to 
afford adequate confidence that the entire oper-
ation will fulfil expected and defined require-
ments for quality of seed stocks of pluripotent 
stem lines. A quality management system 
(QMS) should be implemented that describes 
the organisational structure, responsibilities, 
policies, procedures, processes and resources 
required for QA [84]. The QMS should be based 
on the principles of current good manufactur-
ing practice (cGMP) [83–87], and should con-
sider relevant local regulatory requirements and 
guidance. However, such systems are not neces-
sarily required to be performed under a GMP 
manufacturing license, but should meet a cer-
tain standard (such as the European Union Tis-
sues and Cells Directive, EUTCD [88], which 
assures suitability of the stem cell repositories 
for clinical application and critically establishes 
traceability for all materials and procedures 
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used from the point of informed consent for 
procurement of primary tissue, to the final seed 
stocks. All critical procedures used in delivery 
of the seed stocks should be documented as for-
mally recorded standard operating procedures 
(SOPs), associated forms and higher level docu-
ments such as policies, process descriptions cov-
ering a number of SOPs, manuals and training 
documents. All critical records should be con-
trolled to assure that only the correct and current 
procedures and forms are used and that old ver-
sions are archived carefully to allow review and 
audit in the future. Regulatory requirements will 
also apply to storage and retention times for the 
repository’s critical records including those for 
procurement, facilities, staff training, banking, 
testing, storage and distribution.
Definitions of terms used in QA are impor-
tant to enable the user to comply with the 
regulation. Appendix 7 shows examples of 
such definitions but it should be born in mind 
that, whilst the terminologies used are broadly 
consistent, there can be significant differences 
and the user is advised to check the national or 
locally applicable terms.
 6.2 Risk analysis 
Stem cell repositories should adopt an appropri-
ate risk evaluation model to identify and manage 
risk within the operation. This process usually 
involves the maintenance of a risk register to 
ensure the ongoing monitoring of risk. Reposito-
ries should use risk management to ensure effort 
in assessing risk is appropriately focused. While 
not limited to these items, a risk management 
system should as a minimum:
 Identify and evaluate risks and compile a risk 
register (of note, risk assessment of reagents 
and processes can be managed within the 
Quality System [see section 6.1]);
 Score and prioritize risks;
 Assess residual risk after application of con-
trols already in place;
 Develop action plans for any unacceptable 
residual risks; 
 Regularly review for change and identify new 
risks.
New risks may be identified through various 
routes such as regulatory alerts and reviews of 
emerging diseases. Stem cell repository scien-
tific advisory boards should be used to help iden-
tify new risks as part of their horizon scanning 
activity. 
 6.3 Risk assessment of donor tissues 
and critical reagents 
6.3.1 Donor tissues
Key issues and approaches to microbiological 
risk assessment of donor tissues have already 
been considered in section 4.1.1. In addition, 
evidence for lack of susceptibility of stem cells 
to certain agents can be used to give confidence 
in suitability for clinical use, but these suscepti-
bility profiles have yet to be established for plu-
ripotent cells and their differentiated progeny.
Recommendations for the evaluation of cell 
substrates for production of biologicals, includ-
ing vaccines and biotherapeutics [3,14] have 
identified key issues for risk evaluation of cell 
lines, and these may be helpful in establishing 
testing regimes for seed stocks of hPSC lines. 
The WHO document [3] has also addressed 
some of the key issues for evaluation of stem cell 
lines for the manufacture of biological products 
(see section 8.1). However, regulatory docu-
ments intended for use with the manufacture 
of different kinds of products should be used 
with caution to avoid implementation of inap-
propriate or unnecessary quality control and 
safety testing procedures.
6.3.2 Critical reagents
Critical reagents in the preparation of seed 
stocks of hPSC lines, for the purposes of this 
document, include those materials used in the 
generation of hPSC lines and the production of 
cell banks that come in direct contact with, or 
otherwise could have a critical influence on, the 
properties and safety of the resulting seed stocks. 
Process maps, such as that given in Figure 1, are 
valuable in enabling a complete understanding 
of the derivation and cell banking process (and 
any other process to which they are applied), 
including identification of all critical reagents 
used and key points where cells may be exposed 
to contamination.
Repositories should establish a specification 
and acceptability criteria for all raw materials, 
including the original cell lines if not generated 
by the repository itself. They should also con-
sider auditing suppliers of raw materials [89,90] to 
assure compliance with these specifications. This 
can be an extremely burdensome process and 
may need to be managed, such that the reposi-
tories resource for performing its own audits can 
then be focused by risk assessment. These should 
address risk factors such as the absence of formal 
supplier audit, inappropriate or inadequate QA 
and suppliers of complex biological reagents of 
biological origin.  
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It is important to establish a ‘document trail’ 
for critical reagents. The documents should be 
available from the supplier, who ideally should 
be able to trace the source of raw materials used, 
how they are processed, treated and shipped. 
However, this may not always be the case. 
Accordingly, the development of a supplier 
questionnaire should be considered. With this 
in mind the following list, while not exhaus-
tive nor necessarily sufficient for any particular 
regulator process, is intended as a guide to the 
kinds of issues that may need to be addressed 
when soliciting information from a supplier 
(section 6.8) and assist in prioritizing the need 
for a repository to audit suppliers as discussed 
above:
 Details of the supplier: name, address, tele-
phone number, principal contact and position;
 General information:
 - Description of function e.g., manufacturer, 
distributor etc.
 - Does the supplier sub-contract, and if yes, 
how is control of the subcontract and 
materials achieved?
 - Is there a supplier audit programme or 
vendor rating scheme in place, and how is 
this monitored?
 - Are customers informed of changes to 
their products and how is this information 
transmitted?
 Quality Management System (QMS):
 - Is there a QMS in place?
 - Is there an internal audit programme in place?
 - Is there a document control system in place?
 - Is quality documentation issued with the 
product (e.g., Certificates of analysis)?
 - Where applicable, are certificates for animal 
derived/origin products provided?
 - Are there procedures in place for calibration, 
verification and maintenance of equipment.
 - Is there a procedure to communicate 
regulatory alerts to customers?
 Product Specification questions:
 - Name of product/catalogue number
 - Is QC performed on the product and is this 
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Figure 1.  Example of a process map for derivation of a human embryonic stem cell line. 
Courtesy of C Hunt, UK Stem Cell Bank, NIBSC, 2013.
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carried out by the supplier themselves?
 - What type of QC is carried out and what are 
the pass/fail criteria?
In order for the questionnaire to be of value 
it should also include the date it was completed 
and details of the person completing it on behalf 
of the supplier and any relevant documentary 
evidence to support the answers to the questions.
Supplies of cells used to facilitate the culture 
of hPSC lines (e.g., feeder cells, cells used to 
make cell-conditioned medium or other prod-
uct) should also be subjected to similar evalua-
tion and risk assessment. 
 6.4 Seed stock and clinical trial cell 
bank production and labelling
The suggested structure for an appropriate two-
tier cell banking system (MCBs and WCBs, see 
section 4) is outlined in ISCBI [1]. Sufficient vial 
numbers should be established to meet antici-
pated demand for seed stock cell supply and 
testing that may be required in the near future 
(i.e., next 5–10 years). Contingency to allocate 
seed stock vials for additional testing that may 
be needed will be important. Furthermore, past 
experience in cell banking for cell lines used 
to manufacture vaccines and biotherapeutic 
products, has shown that it can be extremely 
valuable to allow for some additional produc-
tion contingency vials. While it is difficult to 
prescribe numbers of these additional vials, some 
contingency will enable immediate response to 
a sudden increased demand for testing or for 
production cells and avoid delays caused by re-
banking in the future. 
If repositories are providing cell banks 
that are to be used to provide material direct 
into a clinical application (e.g., clinical trial, 
EU hospital exemption) they would usually 
be expected to do so under a Manufacturing 
License with GMP accreditation. This requires 
careful environmental controls [91] and other 
more specific requirements, depending on the 
local jurisdiction [84,87,92]. A glossary of terms 
commonly used in GMP production can be 
found in Appendix 7. However, it is important 
to note that precise definitions of particular 
words in this glossary may vary between regu-
lators, accordingly, Appendix 7 is provided as 
an example only. Repositories should be aware 
of local and international regulatory require-
ments, which will apply to all aspects of the 
facility, including movement of staff and mate-
rials, staff health status and other activities or 
services which in particular, could introduce 
contamination. 
It is essential to assure that cell lines do not 
become switched or transmit microbial contami-
nation to other cells used in the banking and 
storage facility. Accurate labelling (see below) 
and documentation of cell handling processes 
are clearly vital to this and in addition prepara-
tion of cell banks of different cell lines on a ‘cam-
paign’ basis (i.e., one cell line per laboratory at 
any one time with qualified cleaning completed 
between banking events).
All repository systems and equipment that 
may affect the final seed stock quality must be 
monitored for operation between limits estab-
lished for validation (section 6.5), and alarmed 
to warn when out of specified conditions. Where 
temperature limits are key to the process (e.g., 
to prevent storage at inappropriate temperatures) 
the equipment should be alarmed and upper 
(and where appropriate lower) limits set. Alarms 
for other parameters, (e.g., low liquid nitrogen 
[LN
2
] levels, failure of LN
2
 supply) should also 
be in place.
Importantly, stem cell lines and products 
incorporating viable cells cannot be terminally 
sterilized, and it is therefore vital that the condi-
tions of cell banking do not introduce microbio-
logical contamination or permit growth of any 
microorganisms that might already be present. 
Cell culture rooms must be operated to ensure 
environmental contamination is controlled to 
acceptable levels prescribed in appropriate legis-
lation [83,84,86,88]. In addition, documented pro-
cedural controls will be required to reduce the 
risk of introducing or spreading contamination 
and cell banking records should be able demon-
strate that the appropriate procedures were used 
in each case. Both physical and chemical means 
of disinfection may be employed as appropriate 
for specific facilities and equipment. The clean-
ing and disinfection procedures should also be 
validated to show they are effective against likely 
contaminants. 
Labelling is a critical element in assuring 
traceability of materials. Repositories should 
aim to adopt appropriate labelling systems to 
fit the developing norms for supply of cells for 
clinical use. The Information Standard for 
Blood and Transplant (ISBT) 128 system [202] 
developed in the USA by the American Asso-
ciation of Tissue Banks, is now being consid-
ered as a model in other countries and whilst 
unmodified hPSCs are not intended to be used 
directly as therapeutic products, this example 
could be considered as the basis of best practice 
for labelling containers of individual release lots 
of stem cell lines.
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 6.5 Validation
All repository processes, equipment and facili-
ties should be validated to demonstrate they are 
fit for their intended purpose. Validation is the 
documented act of ensuring that any procedure, 
process, equipment, material, activity or system 
actually gives the expected results with adequate 
reproducibility [87]. This approach should include 
implementation of the key elements of validation 
including a user requirement specification (URS), 
impact/risk assessments, and a series of qualifica-
tion stages for equipment (i.e. design qualification 
[DQ], installation qualification [IQ], operational 
qualification [OQ], and performance qualifica-
tion [PQ]). Repositories may also use a valida-
tion master plan that describes the overall phi-
losophy, strategy, and methodology for validation, 
and which equipment, processes and other items 
require validation. A validation matrix or sched-
ule of validation will also be useful to document 
which organisation or contractor is responsible for 
each item subjected to validation. It is important 
that risk assessments are performed in advance 
of validation to ensure critical areas are targeted 
and that any validation performed is appropriate 
and optimised in terms of use of resource. Due to 
commonality of operations this is an area where 
exchange of learning experiences between reposi-
tories can help to reduce the burden of QA. 
Validation should be considered for any equip-
ment used that may impact on the suitability of 
the cell banks for clinical use, such as that used 
in processing, cleaning, environmental moni-
toring, storage and shipment. Equipment such 
as controlled-rate freezers, mechanical refrigera-
tors, LN
2
 storage refrigerators and dry-shippers 
will require appropriate monitoring, such as con-
tinuous temperature monitoring and recording 
when in use, to demonstrate that the required 
conditions are maintained. Shipment devices, 
such as ‘dry shippers’, will also require validation 
to assure fitness for purpose. Critical equipment 
such as heating, ventilation and air condition-
ing (HVAC), biological safety cabinets, particle 
counters, incubators and cold storage should be 
validated. The Pharmaceutical Inspection Co-
operation Scheme [203] and WHO [87] both pro-
vide guidance on related validation, and compli-
ance with national regulation. 
Process validation in particular should be 
considered on a case-by-case basis. Validation 
of routine expansion and banking of cell lines 
will need to take many factors into account, 
including the number and type of interven-
tions required, the culture format being used 
(e.g., open or closed system), transfers between 
processing areas and incubators, and the impact 
of different operators and different cabinets/
rooms. Within the banking process, the cryo-
preservation process itself should be validated 
to demonstrate that cells recovered from cryo-
preservation have the characteristics set out in 
the repository’s cell bank release specification 
for cell lines.
 6.6 Qualification and 
standardization of test methods and 
reagents
Establishing the testing regime for seed stock 
banks has been described and discussed in sec-
tion 4 and Appendix 6. All tests used to establish 
suitability of hPSC seed stocks for clinical use 
should be qualified for use. This qualification 
should address requirements, including but not 
necessarily restricted to, sensitivity, specificity 
and also potential for effects (such as test inhi-
bition) by the hPSC sample components. This 
is most readily achieved by supplying samples 
to testing laboratories accredited for the tests in 
question. Where such accredited testing is not 
available the repository should be able to pro-
vide qualification data for the tests performed. 
Accredited services may be available that can 
provide tests that meet multiple or harmonised 
pharmacopoeia requirements and these may be 
required where the cell line is to be used inter-
nationally [93]. 
Well established surface markers and a wide 
range of gene markers are used in stem cell char-
acterization, and selected reference materials for 
their assay may be useful (e.g., fixed cell prepara-
tions, RNA preparations). Standardized func-
tional assays will need to be developed, and in 
particular standardized pluripotency assays will 
be important to progress in the field as assays 
and reagents vary between laboratories. The 
ISCI has focused on a number of relevant issues 
in this area, including the initial identification 
of standard markers for hESC lines [73]. This 
group has also begun to work on determina-
tion of pluripotency in hPSC lines and further 
international collaborative effort is required in 
this important aspect of pluripotent stem cell 
research, which is fundamental to supporting 
high-quality research data (see www.stem-cell-
forum.net). For an overview on standards in the 
cell therapy area see Sheridan et al. [95] and for an 
over view on cell characterization for cell therapy 
see PAS 93 [93].
Of note, where reagents of biological ori-
gin are clinical products in their own right, 
standardization of their biological activity is 
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often performed under the auspices of WHO 
and its Expert Committee on Biological Stan-
dardization [205]. Most of the WHO Interna-
tional Reference Materials (IRMs) are made 
and distributed by the National Institute for 
Biological Standards and Control (a center of 
the Medicines and Health-care Products Reg-
ulatory Authority [MHRA]) and a listing of 
these materials can be found on the National 
Institute for Biological Standards and Control 
website [206].
Standardization of certain reagents such as 
growth factors used in cell culture may also be 
helpful to enhance reproducibility of cultures 
of hPSC lines. This can in part be achieved by 
the repository establishing specifications and 
acceptance criteria for the properties of com-
plex cell culture components. In addition, cell 
culture assays and control materials can be 
established to determine batch consistency in 
supplies of such factors. Where such reagents 
are used widely it may be feasible to establish 
international reference materials (see previous 
paragraph). Furthermore, for certain reagents 
there are Pharmacopeia reference methods for 
their characterization. 
 6.7 Auditing suppliers and service 
providers
An important element in assuring traceability, 
safety, and thus suitability for repositories of 
hPSCs, is the performance of audits of suppli-
ers of critical reagents and services that would 
impact on the final quality of the cell lines 
offered for clinical use. Such audits may range 
from a paper-based audit (which may be justi-
fied where suppliers operate under relevant and 
independently inspected quality standards) to 
a detailed on-site inspection of procedures and 
documentation. The sharing of such audits 
between repositories could provide both cost- 
and time-saving benefits. However, implement-
ing such a scheme would be challenging and 
repositories would need to be confident in the 
ability of any third party auditor and in the 
consistency of the auditing procedure between 
repositories. Recruiting a common auditor with 
appropriate training and expertise using a com-
mon audit protocol is a possible solution. Such 
an auditor should have previous experience 
with inspecting similar facilities and opera-
tions and should have a regulatory background. 
Alternatively, repositories may decide only to 
use suppliers who are registered and inspected 
by a recognised regulatory body; however, this 
should be done using a risk-based approach.
 6.8 Cell line ‘history file’
Careful evaluation of the information associ-
ated with a stem cell line is necessary to deter-
mine its suitability for developing a clinical 
product. Where the repository has derived 
the hPSC line it can collate this information 
directly under its own QMS. However, where 
this is not the case it is important to avoid wast-
ing time and resource on unsuitable cell lines, 
thus, stem cell repositories should request rel-
evant historical information from the depositor 
and continue to build a documented history 
pertaining to each cell line as it is processed and 
banked. This compiled documentation, some-
times called a cell line ‘history file’, should pro-
vide all information necessary to enable trace-
ability of cell line establishment and processing, 
from the derivation and original transport to 
the repository, through banking, testing, stor-
age and any subsequent distribution. This his-
tory file should also include evidence that the 
cell banking was performed under principles 
of GMP or other suitable conditions where a 
GMP manufacturing license is not applicable 
(i.e., early seed stocks where a final product is 
not identified, whereas MCBs and WCBs for 
specific clinical applications in a clinical trial 
or under Hospital Exemption arrangements, 
would probably be required to be prepared 
under a GMP manufacturing license). For 
example, the EU directive on tissues and cells 
for use in humans [88] is based on the principles 
of GMP, but a manufacturing license under 
EU GMP is not required for cells and tissue 
intended for human application including seed 
stocks of hPSC lines. Some of the key aspects 
that should be considered for inclusion in a cell 
line history file are given in Table 2. Whilst it is 
unlikely to be feasible to include all raw data 
and original information, the history file should 
at least facilitate traceability to that informa-
tion. Where the cell repository receives the cell 
line from a depositor working under a suitable 
quality system, the repository may decide that a 
documented audit (physical site audit or paper 
based) along with traceability (typically an 
anonymized link) to the donor and appropri-
ate informed consent may be sufficient. Where 
such links are not possible the repository will 
need to carry out a risk assessment with respect 
to the acceptability of that line within its own 
jurisdiction and if contingencies cannot be put 
in place to resolve significant risks then the 
repository may decide not to receive the line 
or supply it for restricted purposes such as for 
laboratory research only.  
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Over long periods of time, after the seed 
stocks of cells have been released, quality 
control data may become summarized and/
or archived by suppliers and service providers, 
which means that its retrieval from the original 
source is not practicable or not possible. It is 
therefore important to endeavor to anticipate 
the kinds of critical information that may be 
required many years into the future (e.g., details 
of quality control, information on production 
processes, safety testing data), and obtain and 
store copies of this from the respective sources 
(e.g., raw material manufacturers, testing com-
panies) when the cell line is banked, to form 
part of the cell line ‘history file’ whether the 
cells are stem cell lines or some other propagat-
able cell type.
 6.9 Serious adverse reaction (SAR) 
and serious adverse event (SAE) 
reporting
Events may arise during the provision of cells for 
therapy that indicate potential risk to patients. 
Whenever such events are identified, they are 
required to be investigated for impact on the 
patient and if necessary action taken to mini-
mise the impact and prevent re-occurrence. Two 
kinds of event are generally recognised, a seri-
ous adverse reaction (SAR) and a serious adverse 
event (SAE). Whilst definitions of these may 
vary significantly between regulators, a SAR 
usually refers to a serious adverse reaction related 
to treatment of a patient receiving the therapy 
and a SAE refers to any other occurrences that 
might have an impact on patients receiving the 
Table 2. Examples of information that may be required in a cell line history file.
Section Typical content
Depositor information Name of owner of cell line
Address (registered company and manufacturing sites where applicable)
Primary contact
Telephone number(s)
Evidence of ownership*
Shipping records Signed records of inventory shipped and cross check of received goods, including ‘chain of 
custody’ documentation
Records of temperature monitoring data
Record of courier used
Record of arrival at repository including transport time/temperature and condition on 
receipt
Provenance Donor information related to the donation of primary tissue**
Original, anonymized donor consent and medical history (this may not always be available 
depending on national laws and regulations)
Culture/banking details Description of the culture conditions related to (where applicable): tissue or embryo 
culture; cell line derivation; cell line expansion; reagent documentation, traceability 
and cryopreservation. This should include, for example, passage number (or population 
doublings where possible) of seed lots and subsequent banks that were created up to the 
point of manufacture relevant to the material being received by the repository
Quality control test results Characterization and safety test results both provided by the depositor and generated by 
the repository and given with associated passage or population doubling levels
Facility and equipment details Qualification records: records of use, maintenance, calibration, validation, re-verification, 
repair
Environmental monitoring records Records of and trends in scores of contamination for testing applied to the environmental 
conditions, which may include: viable and non-viable particle counts; active air sampling, 
air pressures, temperature, relative humidity, operator finger dabs, ambient temperatures in 
critical storage areas
Deviations from standard procedures (SOPs) Records of deviations from normal procedure, which may affect the specific cell line, for 
example failure of an incubator in which the line was processed
Change controls Records of change control investigations relevant to the cell line, for example impact of 
changes to QC test specifications or moving storage location of cryopreserved material
Records of staff training and illness of an 
infectious nature
Records of training and return to work procedures to ensure staff infectious status is not a 
risk to cell cultures
*There is a risk to final clinical utility of a particular cell line if all potential owners are not identified at an early stage. Thus, it is important to obtain accurate 
information from the cell provider, about all parties with a potential interest in ownership of the cell line (e.g., sponsors of research, host organisation, principle 
investigator) and to confirm, first, that they are in agreement with the repository receiving and distributing the cells, and second, whether they need to be a signatory 
party to the deposit of the cell line in the repository.
**Detailed donor information may be held by the repository, but special care will obviously need to be taken (and may be a legal requirement) for its control and 
security. For example, in the UK the Caldicot Principles apply to the management of sensitive patient data [215].
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therapy. Repositories clearly need to be aware of 
the regulatory definitions that apply to them.
Most countries have established systems for 
reporting post-donation disease and adverse 
events in clinical trials. Repositories supply-
ing cells that may be used for human applica-
tion should be coordinated within these sys-
tems to ensure that SARs and SAEs related to 
subsequent final products can be traced back 
through the repository and ultimately to the 
primary tissue donor to enable full investiga-
tion of the potential causes. Establishment of 
mechanisms to assure traceability are critical 
in the development of seed stocks, as already 
discussed extensively throughout the earlier 
sections of this document. 
Stem cell repositories supplying cells for clini-
cal use will be expected in the first instance to 
identify, investigate and report SAEs occurring 
in the banking process, which might affect the 
suitability of the cells for clinical use. Second, 
they will also be expected to submit to regula-
tory investigations when SARs or SAEs occur 
in clinical applications using cells they have 
supplied. In such cases, they will be expected 
to demonstrate full traceability on the procure-
ment, banking, testing, storage and supply for 
the cells in question. It is vital that stem cell 
repositories understand their responsibilities 
in these situations and how to manage them 
through appropriate elements of their QMS. 
Within Europe, the Rapid Alert system for 
human Tissues and Cells (RATC) has been 
implemented whereby manufacturers (includ-
ing ‘tissue establishments’ providing cells and 
tissue as starting materials for cell therapies) and 
distributors of medicinal products (including 
advanced therapy medicinal products [ATMPs]) 
are required to report all SARs for medicinal 
products (licensed, unlicensed and clinical trial 
products) to their national competent authority 
within a defined time period under RATC [207]. 
In the EU each national competent author-
ity reports incidents to the Europe-wide phar-
macovigilance web-based AE/AR collection 
system EudraVigilance which is managed by 
the European Medicines Agency (EMA). In 
the USA, the FDA runs MedWatch [209] for 
reporting and monitoring adverse reactions. 
This includes specific guidance for human cell- 
and cellular-based tissue products. EU member 
states are also required to report all adverse inci-
dents to the WHO international drug monitor-
ing programme and this is done by the national 
competent authority. The WHO maintains an 
international system for monitoring adverse 
reactions to drugs using information derived 
from Member States within and beyond the 
EU. The system is run and coordinated by the 
Uppsala Monitoring Center (UMC) in Swe-
den (www.who.umc.org). Similar requirements 
apply in other jurisdictions and a list of noti-
fied bodies in different countries is given in 
Table 3 [208].  
Stem cell repositories should consider the 
International Conference on Harmonisation 
(ICH) guidance on efficacy, which includes 
guidance for pharmacovigilance planning and 
definitions and standards for preparing and sub-
mitting safety reports [209]. Guidance can also 
be obtained from the Council for International 
Organisations of Medical Sciences (CIOMS) 
[210], which was jointly established by the WHO 
and the United Nations Educational Scientific 
and Cultural Organisation.
 6.10 Disaster recovery, contingency 
planning and legacy management
It is necessary that procedures for disaster recov-
ery are in put in place to manage unforeseen 
events that may severely impact on repository 
critical operations (e.g., fire, flood, loss of power, 
failure of liquid nitrogen supply). Repositories 
should at least maintain some local backup stor-
age system such as splitting storage of stocks 
over different equipment and locations. Such 
backups must be maintained under the same 
conditions as the main stocks. Where possible 
repositories should encourage and advise deposi-
tors to secure their own cell stocks for backup in 
this way. Records of banking inventories should 
also be backed up and other critical repository 
documentation on cell bank production either 
backed up or adequately secured. In addition, it 
is necessary to ensure that contingency plans are 
in place to secure the continued availability of 
stored cell lines for appropriate periods of time in 
the event of normal repository operations being 
discontinued. These procedures can be delivered 
within a risk management system as outlined in 
section 6.2.
A course of action should also be defined in 
the event of a planned termination of the reposi-
tory (such as an orderly wind-down when the 
facility is transferred elsewhere) or an emergency 
termination (including loss of key resources, 
funding or regulatory approval). It will also be 
important to distinguish between obligations 
regarding cells intended for human application 
and cells held for research, since the standards 
and conditions required for both cells and 
a ssociated records will be different for each.
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 6.11 Regulation in different 
countries
The regulation for cell-based therapies is still 
at an early stage of development, and progress 
in establishing formal regulatory frameworks 
varies across jurisdictions [96]. As cell therapy 
products are being developed, manufacturers 
will aim to market their products in different 
countries, making knowledge of the differences 
in regulatory frameworks of vital importance. A 
comparison of the regulatory frameworks in the 
EU and the USA has been published by the Brit-
ish Standards Institute (PAS 83) [94]. The ISCBI 
section on the ISCF website has also developed 
information on the national regulatory bodies 
(Table 3) and donor selection procedures in dif-
ferent countries (see Appendix 4), and provides 
relevant policy statements by the ISCF Ethics 
Working Party on cell banking procedures [5,11]. 
Some countries have developed regulatory route 
maps to help national cell/tissue repositories, 
hospitals, and industry negotiate the regula-
tory landscape, and a toolkit used in the UK for 
stem cell therapy [211]. A route map regarding the 
Canadian regulatory framework for the develop-
ment of stem cell-based therapies has been devel-
oped under the auspices of the Canadian Stem 
Cell Network [212].
7. Preservation and storage 
 7.1 Cryopreservation of hPSC lines
Cells can be stored in a stable state through the 
application of appropriate cryopreservation pro-
tocols [96]. Cryopreservation includes a number 
of processing steps both before low-temperature 
storage and again at thawing and culture of 
the cryopreserved material. In addition, mate-
rial must be stored and transported under 
conditions that maintain material stability. 
Cryopreservation protocols generally fall into 
two types: those that incur the formation of 
ice within the system, whether intracellular or 
extracellular (i.e. freezing) and those that avoid 
ice formation (i.e. vitrification). For a review of 
cryopreservation and vitrification methods [97].
In applying or designing an effective cryo-
preservation process, there are a number of key 
technical issues that should be considered:
 Methods for assessing recovery of cells from 
the cryopreservation process
 Choice of cryoprotective agent (CPA)
 Choice of container and packaging
 Mode of cryopreservation (i.e., freezing vs 
 vitrification)
Table 3.  National competent authorities for serious adverse event and serious adverse reaction reporting.
Country National competent authority Program/website
Australia Therapeutic Goods Administration www.tga.gov.au
Brazil ANVISA http://portal.anvisa.gov.br/wps/portal/anvisa-ingles   
Canada Health Canada www.hc-sc.gc.ca/index-eng.php
China National Institutes for Food and Drug Control
National Centre for ADR Monitoring
www.nicpbp.org.cn/en/CL0309
European European Commission Rapid Alert system for human Tissues and Cells http://ec.europa.eu/health/blood_tissues_organs/
docs/ratc_report_2008_2012_en.pdf
Finland Finnish Medicines Agency www.fimea.fi/frontpage 
France French National Agency of Medicine and Health Products Safety, ANSM ansm.sante.fr/Produits-de-sante/Medicaments
Germany Federal Institute for Drugs and Medical Devices www.bfarm.de
www.bfarm.de/EN/Home/home_node.html (English)
India Indian Pharmacopoeia Commission www.ipc.gov.in
Israel Israeli Ministry of Health www.health.gov.il/english
Japan The Pharmaceuticals and Medical Devices Agency www.pmda.go.jp/english
Netherlands Pharmacovigilance Centre Lareb  www.lareb.nl
Singapore Health Sciences Authority www.hsa.gov.sg
South Korea MFDS www.mfds.gov.kr 
Spain Spanish Medicines and Health Products Agency www.aemps.gob.es/en
Sweden Medical Products Agency www.lakemedelsverket.se
Taiwan Bureau of Medical Affairs, Department of Health and Center for Drug 
Evaluation
www.fda.gov.tw
Thailand US FDA, Drug Information Centre and NADRM www.fda.moph.go.th
UK Medicines and Healthcare Regulatory Agency www.mhra.gov.uk
USA US FDA www.fda.gov
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 Method of cooling (passive vs controlled rate 
cooling)
 Storage conditions
 Transportation of cryopreserved material
 Recovery process (i.e., rewarming and elution 
of cryoprotectant)
7.1.1 Assessing recovery from 
cryopreservation
In order to design or optimise any cryopreser-
vation protocol, an assessment of recovery is 
required. Tests using trypan blue or fluorescent 
compounds such as acridine orange/ propidium 
iodide are often referred to as ‘viability tests’, 
but are more truly membrane integrity tests 
[98]. The accuracy of these tests in indicating 
normal function of the cell, particularly the 
complex requirements of hESCs in culture, is 
arguable. Such tests may over- or under-estimate 
the ability of cells to survive, attach, proliferate 
and maintain the undifferentiated state and dif-
ferentiate into the required cell type. Further-
more, cells that still show membrane integrity at 
the time of thawing may die later by apoptosis. 
Such tests should not be employed in isolation. 
It may be necessary to consider evaluation and 
quantification of the viable material at a point 
sometime after thawing, such as 24 or 48 h 
post-thaw. Consideration should also be given 
to use of a range of tests, including appropriate 
functional assays, when assessing recovery from 
cryopreservation [98]. 
7.1.2 Choice of cryoprotectant
In choosing an appropriate CPA, consideration 
should be given to any known specific effect on 
the cells e.g., cytoskeleton effects, membrane 
effects, induction of cell differentiation. In order 
to provide protection, cells must be equilibrated 
in the CPA solution prior to the application of 
cooling. CPAs can be toxic to cells and consid-
eration must be given to the intrinsic toxicity of 
standard compounds which is time, temperature 
and concentration dependent, whether using 
a controlled rate freezing method or vitrifica-
tion [99]. Additives to the solution (e.g., serum) 
should be assessed for their ability to mitigate 
these and other effects.
Cryoprotectant solutions will exert an osmotic 
effect during their addition to and elution from 
the cells. If uncontrolled, such effects can be 
damaging and compromise cell survival. Osmotic 
damage can be reduced or eliminated by the 
use of step-wise addition and elution protocols. 
Single step protocols (e.g., centrifugation and 
re-suspension in medium containing cryoprotec-
tant) should be assessed for their effect on sur-
vival. Step-wise or slow addition or elution pro-
tocols should take into account the likelihood of 
incurring damage from CPA toxicity.
7.1.3 Choice of primary container
For cell suspensions, the choice of primary con-
tainer will generally be conditional on the mode 
of cryopreservation. The most practical and 
generally acceptable options currently available 
are straws, vials and bags. Each option should 
be assessed for its suitability not only for the 
mode of cryopreservation (e.g., whether or not 
the required cooling rate is achievable) but also 
its ability to prevent or reduce contamination 
(primarily during cooling and storage), and its 
compliance with regulatory guidelines (such as 
requirements for labelling of the primary con-
tainer). The use of open systems is not consid-
ered best practice and represents a hazard to 
stored cells (see below).
The primary techniques and methods available 
for preservation of hPSC lines are described by 
Hunt [100] in Appendix 8. Further expert opin-
ion on preservation technologies can be found in 
Day and Stacey [101] and the recently published 
informational general chapter ‘Cryopreservation 
of Cells available in Pharmacopeial Forum section 
39(2)’ [213]. 
7.1.4 Storage conditions
Scientific evidence suggests that storage at ultra-
low, sub-zero temperatures (generally accepted 
to mean storage in or above liquid nitrogen) does 
not result in significant deterioration of mate-
rial over extended periods of time (measured in 
decades, for a review see [102], provided that the 
temperature remains stable and uniform. This 
may be extended to mechanical refrigeration 
at temperatures at or below -160°C. Storage in 
mechanical freezers at -80 to -85°C is acceptable 
for short periods of time if the sample is to be, 
or has been, preserved by freezing, but is likely 
to result in potentially damaging ice formation 
in vitrified samples. If storage at this tempera-
ture is considered necessary, the period of storage 
should be validated to show that the cells do not 
demonstrate any adverse effects. Storage above 
-80°C is not recommended. For vitrified material, 
temperatures above, or repeated cycling through, 
the glass transition temperature (approximately 
-130°C) should be avoided to prevent progressive 
formation of ice crystal nuclei.
The most stable conditions for storing cells at 
ultra-low temperatures are provided by storage 
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under LN
2
. Consideration should be given to 
the potential for cross-contamination of samples 
stored in this manner via the liquid. There are 
a number of reports in the literature that indi-
cate that contaminants, including viruses, can 
survive in LN
2
 and there is at least one report 
of fatal viral transmission through this route. A 
formal risk assessment should be carried out of 
sample containment (i.e., primary and second-
ary containers), and alternatives to such condi-
tions considered. Leakage of LN
2
 into the sample 
container also represents an explosive hazard 
when samples are removed from storage.
Storage in the gas phase above liquid nitrogen 
(often referred to as vapour-phase storage) has 
been recommended. Such storage, while reduc-
ing the risk of cross-contamination, increases the 
likelihood for temperature instability from the 
inherent temperature gradient between bottom 
and top of the LN
2
 refrigerator. This tempera-
ture gradient may be reduced or eliminated by 
modification to, or purchase of, tanks designed 
to reduce this temperature gradient. Storage 
refrigerators are available that exclude LN
2
 from 
the storage compartment altogether (referred to 
as isothermal vessels) or restricted it to areas 
below the sample containers, for example by the 
use of vapour-phase platforms. Temperature gra-
dients are reduced or eliminated either through 
jacketing the vessel with LN
2
 (the isothermal 
approach) or through the use of a heat-shunt 
device within the tank or through design of low-
loss access to the vessel. 
7.1.5 Recovery of frozen or vitrified 
materials
Cells can be damaged through inappropriate 
thawing and CPA elution protocols. In general, 
rapid warming (at 37–40°C) is considered more 
effective in preventing cell damage from intra-
cellular ice formation or solution effects of the 
CPA during rewarming. Rapid warming is espe-
cially important for vitrified material; however, 
care must be taken to prevent thermal runaway 
and exposure of the thawed material to elevated 
temperatures where the temperature-dependent 
toxic effects of the CPA may damage the cells. In 
designing or applying a cryopreservation protocol 
consideration should be given to the method of 
rewarming and the freezing/vitrification protocol 
optimized to that particular rewarming procedure. 
Consideration should also be given to the 
method of eluting the CPA to prevent osmotic 
damage. The use of non-permeating compounds 
such as sucrose or mannitol to prevent excessive 
swelling may be considered. Recipients should 
be provided with validated thawing and elution 
protocols and a mechanism for adverse event/
adverse incident reporting. 
 7.2 Shipment
In Europe there is specific legislation for the 
import and export of tissues [88], which also has 
technical annexes which prescribe aspects of cell 
and tissue procurement, processing, storage and 
testing. However, the situation is highly vari-
able around the world. In some countries such 
as Israel, a simple statement of commercial worth 
is required, whereas in Taiwan there are specific 
import and export regulations, and in some 
countries such as Singapore, these issues are still 
under consideration (to the best of the authors’ 
knowledge at the time of publication). 
Competent couriers are critical to efficient 
shipment, and it is best that repositories take 
responsibility for using couriers that have good 
knowledge of local requirements for import. It is 
also important for stem cell repositories to have 
service level agreements with couriers that iden-
tify standards of service and emergency proce-
dures where cryogens become depleted. 
Cells cryopreserved by slow cooling may be 
transported in dry ice. Vitrified material should 
not be transported in dry ice (solid CO
2
) at 
-79°C, to avoid de-vitrification and cell dam-
age. Cells cryopreserved by either method may 
be transported in LN
2
 dry-shippers which are 
probably the most secure form for transport. 
Repositories should identify transportation com-
panies with the required technical expertise to 
undertake such shipments. Where this is likely to 
involve shipments outside of the country of origin, 
repositories should be familiar with the regulatory 
requirements pertaining to the safe shipment of 
cells in dry shippers. Use of air freight couriers 
that avoid transportation on commercial passen-
ger airlines may reduce problems associated with 
a lack of knowledge of shipping in dry shippers 
or dry ice shippers. Where cells are transported 
in the absence of temperature data-loggers, con-
sideration should be given to the use of chemi-
cal or other indicators to provide information on 
temperature during transportation. 
8. Future applications of human 
pluripotent stem cell lines
 8.1 Evaluation of human stem cell 
lines for production of biological 
medicines
Apart from cell therapy, stem cells or cell lines 
derived from stem cells can be envisaged for use 
as substrates for the production of biological 
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medical products such as recombinant proteins 
(e.g., growth factors or monoclonal antibodies), 
vaccines and conditioned media. A ISCBI sub-
group including representatives from the phar-
maceutical industry, reviewed the requirements 
for cells used to manufacture such products and 
provided the following summary. 
Guidelines for the testing of diploid cells, 
continuous cell lines and stem cells for cell 
seed, MCB, WCB and end of production cells 
have been provided by Part B of the document, 
“WHO Recommendations for the evaluation of 
animal cell cultures as substrates for the manu-
facture of biological medicinal products” [3]. In 
cases where a stem cell line has a finite lifespan 
(senescence) and a diploid profile, the ISCBI 
manufacturing sub-group recommended assess-
ment of the basic characteristics of a stem cell 
line by following the criteria of other accepted 
diploid cell lines such as MRC-5 for biologics 
production. In the case of a stem cell line with a 
continuous cell line profile (unlimited capacity 
for population doubling), the group considered 
that the stem cell line can be included in the 
continuous cell line classification. As stated 
by WHO, this proposal can be applied to any 
animal stem cell lines including human stem 
cell lines.
Depending on the product that is made, the 
sub-group also proposed reference to the guide-
lines described in Table 4.
In addition, specific recommendations for the 
testing of each product type should be tailored 
to the origin and the derivation process of the 
stem cell line and to the functions of the prod-
uct on a case by case basis. The risks related to 
contaminants from the stem cell line have to be 
considered in the testing of each product, that 
is, viruses, retroviruses and other transmissible 
agents, cellular DNA, cellular proteins (growth-
promoting proteins).  
 8.2 Preparation of pluripotent stem 
cell lines for use in toxicology assays
The capability of human stem cell lines to create 
tissue-like cultures in vitro, could provide valu-
able information on the toxicity of medicines 
and hopefully avoid some of the serious chronic 
toxic effects of drugs which were not detected by 
standard assays [103,104]. The principles of GCCP 
[63] are directly relevant to the use of the undif-
ferentiated hPSC lines used in the development 
of toxicology assays. As part of the EC funded 
multi-consortium cluster SEURAT-1 [214] con-
sideration has also been given to the kinds of 
specific quality control measures needed for 
hPSC lines and their development [105]. A diverse 
range of differentiation protocols are being used 
to develop these assays and the establishment of 
assay control parameters, and possibly reference 
preparations of toxicants to provide quality con-
trol of the differentiated cultures. This will be 
vital to ensure reproducibility in assay data and 
will be paramount for the successful utilization 
of stem cell-based models in toxicology and drug 
discovery. 
Table 4. Documents providing guidelines for manufacture of biologics from stem cells.
Guidelines Vaccines Recombinant 
proteins
Conditioned 
media
WHO/ DRAFT/ 4 May 2010: Recommendations for the evaluation of animal cell 
cultures as substrates for the manufacture of biological medicinal products and for 
the characterization of cell banks (proposed replacement of TRS 878, Annex 1). See 
reference WHO 2010a
√ √ √
International Conference on Harmonization, Q5D, Derivation and Characterization 
of Cell Substrates Used for Production of Biotechnological/Biological Products, 1997. 
www.ich.org/LOB/media/MEDIA429.pdf 
√ √
International Conference on Harmonization, Q5A, Viral Safety Evaluation of 
Biotechnology Products Derived from Cell Lines of Human or Animal Origin. www.ich.
org/LOB/media/MEDIA425.pdf
√ (a) √
International Conference on Harmonization, Q5B, Quality of Biotechnological 
Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA 
Derived Protein Products. www.ich.org/LOB/media/MEDIA426.pdf
√ (b) √
CBER Guidance for Industry, Characterization and Qualification of Cell Substrates 
and Other Biological Starting Materials Used in the Production of Viral Vaccines 
for the Prevention of Infectious Diseases, 2010. www.fda.gov/downloads/
BiologicsBloodVaccines/GuidanceComplianceRegulation
√
(a) Applies to recombinant subunit vaccines. Inactivated vaccines, all live vaccines containing self-replicating agents, and genetically engineered live vectors are 
excluded from the scope of this document.
(b) Applies to subunit vaccines only.
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Appendices
Appendix 1
Appendix 1 (a). Compliance and provenance determination.
(1) Embryo provenance determination Code Considerations
  (a) Independent review and oversight   B   The protocol for obtaining gametes and embryos from living donors 
should be subject to independent review. Review and approval of the 
hESC derivation protocol may be required in some jurisdictions, but is not 
an essential requirement
  (b) Voluntary informed consent   B   hESC-specific consent requirements may exist or subsequent users of hESC 
lines may be required to obtain lines for which comprehensive consent 
has been obtained. Bank should seek to obtain documentation of consent 
protocol
  (c) Gratuitous donation   B   Banks should receive assurance that donors were not paid for embryos or 
storage costs
(2) Compliance determination Code Considerations
  (a1) Embryo was donated in a jurisdiction with 
no explicit prohibition on hESC derivation
  B   Accepting embryos from jurisdictions where hESC research is restricted 
may incur legal liability
  (a2) Derivation protocol confirms to any unique 
legal requirements in jurisdiction where hESC 
derived
  B   Jurisdiction may have unique requirements in addition to international 
standards for research ethics (e.g., embryo research oversight or licensing); 
Consistent with 1a
  (b) Any line derived using IVF for research 
purposes, parthenogenesis or SCNT is 
identified
  B   The use of hESC lines derived from embryos created for research purposes 
are prohibited by some jurisdictions and funding bodies
  (c) Consent requirement for third-party gamete 
donors
  A   Some donated embryos may have been created using gametes from 
someone other than the embryo donor; Some jurisdictions require consent 
from third-party donors
  (c1) hESC lines derived from embryos intended 
for reproductive use where a third-party 
donor(s) was contracted to provide gametes
  A   Bank or entity performing hESC derivation should review donor/recipient 
contract for any conditions that would restrict research use
  Policies regarding the use of such embryos or resulting hESC lines are 
variable. Bank should review egg-sharing contract or exchange policies
  Certain end-users may not be able to utilize lines derived from embryos 
for which gamete donors were paid or where egg sharing, exchange or 
anonymous donation has taken place. Documentation serves to enable 
end user to perform use eligibility determination
  (c2) hESC lines derived from embryos for which 
gamete donor(s) participated in egg sharing or 
exchange programs are identified
  A
  (c3) hESC lines derived from embryos created 
with anonymous gamete donation are 
identified
  A
   (d) Donor medical history   A/PU   Requirement for medical history may vary depending on relationship 
between donor and recipient of embryo for IVF. If embryos are created 
specifically for research, gamete donor medical history should be obtained 
Code Key:
A Advisable (recommended?): Level of attainment recommended at this time by the International Stem Cell Banking Initiative.
B Baseline: Minimum level of attainment generally consistent with the current standard of care for clinical grade stem cell lines.
NR Not recommended: This option not recommended at this time. Consideration subject to revision based on new information.
PU Potentially utility if available but not required: In certain circumstances supplemental information: medical records, biological specimens (e.g., blood or urine 
specimens) or quality control assays may be available or have been performed. Banks are encouraged to retain access to supplemental information. Absent 
evidence of utility –  safety or clinical efficacy –  the acquisition of supplemental information should not be required for the development of clinical grade 
stem cell lines.
hESC: Human embryonic stem cell; SCNT: Somatic cell nuclear transfer.
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Appendix 1 (b). Informed consent and donor disclosures: compliance determination check list.
2.1 Did the informed consent process communicate the following elements?
That the somatic tissue/cells would be used for the purpose of stem cell research, including the derivation of stem 
cell line(s).
That genetic tests may be performed, including whole-genome sequencing.
That research may be conducted on human transplantation. 
That the research is not intended to provide direct benefit to the donor(s) except in the case of autologous 
donation.
That the cell lines might be used in research involving genetic manipulation of the cells. 
That the cell lines might be used in research involving the mixing of human and nonhuman cells in animal models.
That the research entails both foreseeable risks and benefits.                                                        
That any stem cell lines created may be used and stored indefinitely.
That any stem cell lines created may be used in future unspecified research projects.
That the decision whether to donate would not affect future medical care. 
That confidentiality will be maintained.
That the cells would be coded or anonymized (i.e. irreversibly de-linked). 
That donor recontact may be possible (unless anonymized).
That the donor was informed concerning the disclosure (or not) of general, individuals and/or incidental findings.
That the donor was informed of the right of withdrawal provided this is not overridden by complete anonymization.
That the stem cell lines derived will be deposited in a repository for long-term storage and use.
That once the cells have been used in research, the donor will have no further control over any use of the cells or 
derived stem cell lines.
That the cells may be distributed to researchers and institutions within and beyond Canada.
That the cell lines may be used for commercial purposes but without financial benefit to the donor.
That the donor was informed of the researchers’ actual or potential conflicts of interests.
Yes No N/A
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Appendix 2. Material transfer agreements
A material transfer agreement (MTA) is a contract that governs the transfer of tangible research materials between two organizations 
(the provider, who is the owner/custodian or the authorized licensee of the material and associated data, and the recipient), thereby 
defining the contractual rights and obligations with respect to the materials and any derivates. 
Important issues to consider when drafting or evaluating an MTA include:
 Ownership of the materials.
 Definition and legal status of original/biological materials, modifications of materials and derivates, progeny;
 Definition of commercial purposes, non-profit organizations, investigator or researcher
 Intellectual property rights;
 Publication rights;
 Royalty fees
 Confidentiality;
 Scope of use and restrictions (e.g., non-commercial/academic vs. commercial research; ethical limitations on types of research to 
be conducted (e.g., limitations on research aimed at the generation of gametes);
 Use of materials in sponsored research (e.g., industry vs. industry/academic sponsored research);
 Transferability of cell line , cell products or data derived from cell products (e.g., genetic sequencing data);
 Conflicts with existing agreements;
 Compliance with laws and ethical guidelines;
 Processing, cost-recovery and other fees
 Warranties;
 Liability;
 Indemnification.
Model material transfer agreements.
UK Stem Cell Bank Clinical/Commercial use http://www.ukstemcellbank.org.uk/cell_lines/eutcd_grade_stem_cell_lines/
depositing_eutcd_stem_cell.aspx
Research Use
http://www.ukstemcellbank.org.uk/legal_agreements.aspx
USA National Institutes of 
Health (NIH), Center for 
Regenerative Medicine (CRM)
Master Agreement Regarding Use of the Uniform Biological Material Transfer Agreement
http://www.crm.nih.gov/researchTools/uniform_transfer_agreement.asp
CRM Induced Pluripotent Stem (iPS) Cell Material Transfer Agreement
http://www.crm.nih.gov/researchTools/material_transfer_agreement.asp
Public Health Service Biological Materials License Agreement
http://www.crm.nih.gov/researchTools/bio_mats_agreement.asp
International Society for Stem 
Cell Research (ISSCR)
ISSCR Sample Material Transfer Agreement
http://www.isscr.org/home/publications/guide-clintrans/sample-material-transfer-agreement
ATCC General MTA
http://www.atcc.org/Documents/Product%20Use%20Policy/Material%20Transfer%20Agreement.aspx
Research Use
http://www.atcc.org/en/Documents/Product_Use_Policy/Research_Use.aspx
Commercial Use
http://www.atcc.org/en/Documents/Product_Use_Policy/Commercial_Use.aspx
California Institute for 
Regenerative Medicine (CIRM)
http://www.cirm.ca.gov/our-funding/stem-cell-regulations-governing-cirm-grants
BioTimes hESC Lines
http://www.cirm.ca.gov/our-funding/biotime-stem-cell-lines-agreement
WiCell iPS Wisconsin MTA
http://www.wicell.org/media/WiCellAgreements/WiCell-iPS-MTA.pdf
UCSF MTA
http://www.wicell.org/media/WiCellAgreements/WiCell-UCSF-Material-Agreement.pdf
Wisconsin Alumni Research 
Foundation (WARF)
Agreements
http://www.warf.org/home/for-industry/Agreements/agreements.cmsx
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Appendix 3. Compliance determination: specific issues to consider for hESCs.
Embryo donation/
hESC derivation
Some jurisdictions explicitly prohibit the derivation of hESC from human embryos. It is not uncommon for 
individuals residing in prohibitive jurisdictions to inquire about research donation to outside research centers or 
banks. Embryos originating from prohibitive jurisdiction should not be used for the derivation of hESC lines if an 
explicit prohibition is/was effective at the time of donation.
IVF for research 
purposes & 
parthenogenesis
Some national, sub-national jurisdictions or funding organizations impose limits on hESC line eligibility. For 
example, certain jurisdictions have adopted explicit policies determining which hESC lines may be used in research, 
including requiring that such lines only be derived from embryos that were created using in vitro fertilization for 
reproductive purposes and were no longer needed for this purpose. This reproductive use requirement prevents the 
use of IVF to develop hESC lines specifically for clinical application or the use of parthenogenetic lines. 
Consequently, lines derived from oocytes (parthinodes) or embryos created for non-reproductive use should be 
identified as such.
Special 
considerations for 
third-party gametes
Most established hESC lines have been derived from embryos that were created using in vitro fertilization for 
reproductive purposes and were no longer needed for this purpose. Gametes used in the creation of reproductive 
embryos frequently come from intimate partners. There are, however, a proportion of embryos created with 
gametes from third-party donors. The conditions surrounding the procurement of third-party gametes may 
influence the compliance determination and should be documented to the extent feasible. Potential factors to 
consider include the following:
•	 Paid gamete donation: oocyte and sperm donors are routinely financially compensated. Some policies limit the 
use of hESC lines derived from embryos for which gamete donors were paid [4]. Banks should be aware of any 
payment or financial compensation restrictions in their jurisdiction. In addition, it should be noted that certain 
funding organizations have restrictions on the use of hESC lines derived from embryos where gamete donors 
were financially compensate beyond the reimbursement of expenses.
•	 Use restrictions: it is also advisable to review the donor contract to support provenance determination and ensure 
there is no clause in the contract that the resulting embryos be used exclusively by the couple to which they were 
donated or otherwise restricting research use.
•	 Oocyte sharing/exchange programs: various mechanisms exist for the financing of fertility treatment. One 
mechanism is ‘egg sharing’ where fertility treatment costs are reduced for the donor who consents to donating a 
portion of her oocytes to other women seeking treatment for infertility. Jurisdictional variations exist in the 
interpretation of this kind of arrangement as a financial incentive, compensation or payment.
It is important to note that the applicability of the above factors relating to third-party gametes will vary by 
national, local or supra-national jurisdictions. For instance, all embryos created using in vitro fertilization for 
reproductive purposes and no longer needed for this purpose are potentially eligible in some jurisdictions regardless 
of third-party donor payment or exchange. However, in other jurisdictions hESC lines derived from embryos for 
which a gamete donor(s) were paid are not eligible for research or funding. Documentation of the factors above by 
the banking entity will enable end users to determine if specific lines are eligible for use in their jurisdiction, but 
such documentation should not be viewed as essential prerequisite for banking.
Appendix 3. Compliance determination: specific issues to consider for hESCs
Prior to initiation of hESC derivation protocol or intent to bank a hESC line, the following compliance issues should be considered 
(see Appendix 1 to 3).
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Appendix 4. Donor screening protocols for assisted reproductive treatments
The majority of existing hESC lines have been derived from embryos intended for assisted reproductive treatments (ART). Cells 
differentiated from hESC lines have been utilized in clinical trials after extensive safety evaluation by national regulatory bodies. 
These evaluations incorporate the donors’ medical history and tests that are required in the context of ART treatments for screening 
low-risk donors of gametes. Consequently, there is no evidence at this time to support the need for further screening of donors of 
embryos used to derive clinical grade hESC lines [8].
Screening assays occurring prior to hESC derivation should be documented. It is sufficient to verify testing was performed in 
accordance with prescribed regulatory requirements. For instance, gamete donation (from non-intimate partners) is generally regu-
lated as a biological product and, therefore, subject to both donor infectious disease testing and sample screening (21 CFR part 1271, 
subpart C, Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the 
donation, procurement and testing of human tissues and cells ). Verifying tests performed (as opposed obtaining quantitative results) 
is sufficient. Testing and screening regulations have evolved over time, so the bank should seek to document the specific screening 
requirements in place at time of gamete donation. 
ART embryos created with anonymous gametes donors should be acceptable for clinical use provided that first, the donor contract 
is sufficient to support provenance determination (see section 1 Governance and Ethics); and second, gametes and/or gamete donor 
were subject to any required screening and testing for relevant communicable disease agents and diseases (see section 4).
Appendix 4. hESC lines: additional donor screening and medical records.
Third-party (allogeneic) 
donation from ART
In the case of gamete donation for the purpose of embryo creation, medical history requirements may 
vary depending on the relationship between the donors and the individuals undergoing ART treatment as 
well as jurisdictional policy. A third-party gamete donor would typically undergo medical screening and a 
medical history will be obtained. Entities deriving hESC lines have demonstrated the ability to obtain 
third-party medical history information (www.cirm.ca.gov/CIRMCellLines). Researchers deriving new 
hESC lines should inquire about the availability of medical history information. Due to privacy and 
contractual considerations it is generally not possible to re-contact third-party donors. Again, it should be 
noted that donor-screening requirements have evolved over time, so it is critical to document the time 
when gamete donation occurred.
Self (autologous) donation 
from ART
Embryos created from the gametes of sexually intimate partners for self-reproductive use are not 
necessarily subject to the same screening requirements as third-party (allogeneic) donation. Resulting ART 
embryos are generally regulated in a manner consistent with requirements for autologous human 
transplantation. In this case, the individual(s) donating the embryo(s) for hESC derivation are the gamete 
donors. A medical history is generally performed in the context of ART treatment and may be available. A 
medical screening and history may also be obtained at time of embryo donation with donor consent. 
There is evidence from hESC derivation protocols that donors may consent to (1) being re-contacted in 
the future or (2) allow linkage to their medical records [8]. Consequently, entities deriving or banking 
clinical grade lines should examine the possibility of donor re-contact and record linkage options when 
possible.
Gamete donation for research 
purposes
Blastocysts may also be made specifically for research using assisted reproductive technologies. In this 
case, it is recommended to obtain a medical history at the time of gamete donation to inform risk 
assessment. When available, banks should associate anonymous medical history with the banked hESC 
lines. Banks may also seek to determine whether the donor(s) of gametes used to derive the hESC line 
underwent a previous medical screening or history consistent with requirements for tissue intended for 
allogeneic human transplantation. The nature and extent of such screening should be documented.
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CANADA Standard Z.900.1 “Cells, Tissues and Organs for Transplantation: General requirements”. Canadian Standards 
Association. (2nd edition under review)
Safety of Human Cells, Tissues and Organs for Transplantation Regulations (SOR/2007–118) (Enabling Statute is 
the Food and Drug Act)
http://www.laws.justice.gc.ca/en/SOR-2007–118/FullText.html
Guidance Document for Cell, Tissue and Organ Establishments (Safety of Human Cells, Tissues and Organs for 
Transplantation- April 6th, 2009)
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/brgtherap/cell/cto_gd_ld-eng.pdf
Transplantation Registration Application Form 
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/compli-conform/frm_0171-eng.pdf
Annex E (normative) Exclusionary Criteria for Risk Factors Associated with HIV, HBV, and HCV
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/brgtherap/cto-reg-annexe-eng.pdf
Regulations Amending the Food and Drug Regulations (1024—Clinical Trials)
(Division 5: Drugs for Clinical Trials Involving Human Subjects)
 http://www.hc-sc.gc.ca/dhp-mps/compli-conform/clini-pract-prat/reg/1024-eng.php
Canadian Institute for Health Research Updated Guidelines for Human Pluripotent Stem Cell Research 2010.
FRANCE Bioethics Law (2004)
Arrêté du 21 décembre 2005 pris en application des articles R. 1211–14, R. 1211–15, R. 1211–16 et R. 1211–21 
du code de la santé publique  
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000456466&dateTexte=
Décret n° 2005–1618 du 21 décembre 2005 relatif aux règles de sécurité sanitaire portant sur le prélèvement 
et l’utilisation des éléments et produits du corps humain et modifiant le code de la santé publique (partie 
réglementaire)
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000636261&dateTexte=
Arrêté du 11 avril 2008 relatif aux règles de bonnes pratiques cliniques et biologiques d’assistance médicale à 
la procréation 
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000018829426&dateTexte=
Décret n° 2008–588 du 19 juin 2008 transposant en matière de don de gamètes et d’assistance médicale à la 
procréation la directive 2004/23/CE du Parlement européen et du Conseil du 31 mars 2004  
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000019060568&dateTexte=
UNITED STATES Guidance for Industry. Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-
Based Products (HCT/Ps)
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Tissue/ucm091345.pdf
International Compilation of Human Research Standards (2012)
http://www.hhs.gov/ohrp/international/intlcompilation/intlcompilation.html
SINGAPORE Guidelines for Healthcare Institutions Providing Tissue Banking: Regulation 4 of the Private Hospitals and 
Medical Clinics Regulation 
http://www.moh.gov.sg/mohcorp/uploadedFiles/Publications/Guidelines/institutions_providing_tissue_
banking_guidelines.pdf
Medicines Act (Chapter 176, ss. 18 and 74) Medicines (Clinical Trials) Regulations
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/legislation/medicines_
act.Par.41439.File.dat/MEDICINES%20(CLINICAL%20TRIALS)%20REGULATIONS.pdf
Medical (Therapy, Education and Research) Act
http://statutes.agc.gov.sg/non_version/cgi-bin/cgi_retrieve.pl?actno=REVED-175&doctitle=MEDICAL%20
%28THERAPY%2c%20EDUCATION%20AND%20RESEARCH%29%20ACT%0a&date=latest&method=part
Human Organ Transplant Act
http://statutes.agc.gov.sg/non_version/cgi-bin/cgi_retrieve.pl?actno=REVED-131A&doctitle=HUMAN%20
ORGAN%20TRANSPLANT%20ACT%0a&date=latest&method=part&sl=1
Appendix 5. Donor selection, eligibility, release criteria and screening procedures: normative and 
institutional documents
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SPAIN Real Decreto 1301/2006 (10 Noviembre, 2006) por el que se establecen las normas de calidad y seguridad para 
la donación, la obtención, la evaluación, el procesamiento, la preservación, el almacenamiento y la distribución 
de células y tejidos humanos y se aprueban las normas de coordinación y funcionamiento para su uso en 
humanos.
Ley 14/2006 (26 Mayo, 2006) sobre técnicas de reproducción humana asistida.
Real Decreto 65/2006 (30 Mayo, 2006) por el que se establecen requisitos para la importación y exportación 
de muestras biológicas.
Plan Nacional de Sangre de Cordón Umbilical. 
http://www.ont.es/infesp/DocumentosDeConsenso/plannscu.pdf
Programa de Garantía de Calidad en el proceso de donación. Organización Nacional de Transplantes.
http://www.ont.es/infesp/Paginas/ProgramadeGarantiadeCalidad.aspx
Real Decreto 2132/2004 begin_of_the_skype_highlightingend_of_the_skype_highlighting, de 29 de octubre, 
por el que se establecen los requisitos y procedimientos para solicitar el desarrollo de proyectos de 
investigación con células troncales obtenidas de preembriones sobrantes (BOE 30 octubre).
Ley 14/2007, de 3 de julio, de Investigación biomédica.
ORDEN SCO/393/2006, de 8 de febrero, por la que se establece la organización y funcionamiento del Banco 
Nacional de Líneas Celulares.
Banco Nacional de Líneas Celulares requisitos para depósito y acceso
http://www.isciii.es/htdocs/terapia/terapia_bancocelular.jsp
Requisitos que debe cumplir la Hoja de Información a los Participantes y el Consentimiento Informado para 
investigaciones que impliquen la generación de células pluripotentes inducidas (iPS) 
http://www.isciii.es/htdocs/terapia/terapia_comiteetica.jsp
Real Decreto 1527/2010 (noviembre, 2010) por el que se regulan la Comisión de Garantías para la Donación y 
Utilización de Células y Tejidos Humanos y el Registro de Proyectos de Investigación
http://www.boe.es/boe/dias/2010/12/04/pdfs/BOE-A-2010–18654.pdf
INDIA Guidelines for Stem Cell Research and Therapy. Department of Biotechnology and Indian Council for Medical 
Research (2013)
The Assisted Reproductive Technologies (Draft Regulation), Rules – 2010. Ministry of Health and Family 
Welfare, Government of India. 
The Assisted Reproductive Technologies (Draft) Bill. Ministry of Health and Family Welfare, Government of 
India
AUSTRALIA Therapeutic Goods (Charges) Amendment Act 2010 (No. 53, 2010). An Act to amend the Therapeutic Goods 
(Charges) Act 1989, and for related purposes.
Australian code of good manufacturing practice for human blood and blood components, human tissues and 
human cellular therapy products (2013)
National Statement on Ethical Conduct in Human Research (2007), developed jointly by National Health and 
Medical Research Council, Australian Research Council and Australia Vice-Chancellors’ Committee
Ethical Guidelines on the use of assisted reproductive technology in clinical practice and research (June, 2007), 
National Health and Medical Research Council.
NHMRC Embryo Research Licensing Committee, Information Kit, National Health and Medical Research Council 
(2008).
UNITED KINGDOM UKSC Bank, MRC, Code of Practice for the use of Human Stem Cell Lines (April, 2010)
HFEA Code of Practice (8th edition), HFEA (2009) 
The Human Fertilisation and Embryology Act (2008)
UK Stem Cell Tool Kit http://www.sc-toolkit.ac.uk/home.cfm
Data and Tissues Tool Kit http://www.dt-toolkit.ac.uk/home.cfm
HTA Code of Practice on Research (2009)
Human Tissue Act (2004)
Human Tissue (Quality and Safety for Human Application) Regulations 2007
British Standards Institute (BSI) Publicly Available Specification PAS 83:2012 Developing human cells for clinical 
applications in the European Union and the United States of America. Guide
BSI Publicly Available Specification PAS 84:2012 Cell therapy and regenerative medicine. Glossary
BSI Publicly Available Specification PAS 93:2011. Characterization of human cells for clinical applications. Guide
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SWEDEN Tissue Law: Lag (2008:286) om kvalitets- och säkerhetsnormer vid hantering av mänskliga vävnader och celler, 
som reglerar hanteringen av vävnader och celler som ska användas för transplantation, assisterad befruktning 
och tillverkning av läkemedel. 
Lagens bestämmelser konkretiseras ytterligare i de föreskrifter som tagits fram av Socialstyrelsen respektive 
Läkemedelsverket.ocialstyrelsens föreskrifterom donation och tillvaratagande av vävnaderoch celler; beslutade 
den 18 november 2008.
SWITZERLAND Federal Act of 19 December 2003 on Research Involving Embryonic Stem Cells (Stem Cell Research Act, StRA) 
(RS 810.3, Loi relative à la Recherche sur les Cellules Souches (LRCS)), http://www.admin.ch/ch/e/rs/c810_31.
html
Federal Act of 18 December 1998 on Medically Assisted Reproduction (Reproductive Medicine Act, RMA) (RS 
810.1 Loi fédérale du 18 décembre 1998 sur la procréation médicalement assistée (LPMA) www.admin.ch/ch/f/
rs/c810_11.html
Federal Act of 8 October 2004 on the Transplantation of Organs, Tissues and Cells (Transplantation Act)
The Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA) , in force since 1st 
January 2002 (www.admin.ch/ch/e/rs/c810_21.html)
Federal Office of Public Health (www.bag.admin.ch/index.html?lang=en)
Swissmedic (Swiss agency for the authorisation and supervision of therapeutic products): the responsible 
regulatory authority on behalf of the Federal Office of Public Health (www.swissmedic.ch/index.html?lang=en)
JAPAN The Act of Pharmaceuticals and Medical Devices
MHLW: Ministry of Health, Labor and Welfare (25/11/2014) 
Revision of former Pharmaceutical Affairs Act. 
Producing regenerative and cellular therapeutic products in firms
The Act on Safety of Regenerative Medicine 
MHLW (25/11/2014)
Providing regenerative medicines within hospitals and clinics.
The previous guidelines ”The Guideline on clinical research using human stem cells” and “Ethical Guidelines for 
Clinical Research” were abolished.
Guidelines on Ensuring Quality and Safety of Products Derived from Processed Human Cell/Tissue
Autologous: MHLW Notification No.0208003 (8/2/2008)
Allogeneic: MHLW Notification No.0912006 (12/9/2008)
Guidelines on Ensuring the Quality and Safety of Products Derived from Processed Human Stem cells
Autologous Somatic Stem Cells: MHLW Notification No.0907–2 (7/9/2012) 
Allogenic Somatic Stem Cells: MHLW Notification No.0907–3 (7/9/2012) 
Autologous iPS(-Like) Cells: MHLW Notification No.0907–4 (7/9/2012) 
Allogenic iPS(-Like) Cells: MHLW Notification No.0907–5 (7/9/2012) 
Embryonic Stem Cells: MHLW Notification No.0907–6 (7/9/2012)
Guidelines on the Derivation of Human Embryonic Stem Cells
Guidelines on the Distribution and use of Human Embryonic Stem Cells 
MEXT : Ministry of Education, Culture, Sports, Science & Technology (25/11/2014)
Revision of regulations for clinical use of hES cells
THAILAND Thai Medical Council Regulation (November, 2009)
Thai Food and Drug Administration Regulation (March, 2009)
Medica
l Council’s Medical Practice Act BE2525 (AD 1982)
Division of Medical Registration of the Department of Health Service  Support’s Sanatorium Act BE 2525 (AD 
1982)
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SOUTH KOREA Bioethics and Safety Act (Jun, 2008) http://www.moleg.go.kr/FileDownload.mo?flSeq=25769 (Article 15)
Enforcement Decree of Bioethics and Safety Act (Nov, 2009)  http://www.moleg.go.kr/FileDownload.
mo?flSeq=31613
Enforcement Rule of Bioethics and Safety Act (Dec, 2009) http://www.moleg.go.kr/FileDownload.
mo?flSeq=31607
Pharmaceutical Affairs Act (Apr, 2007)
Enforcement Decree of Pharmaceutical Affairs Act (Jun, 2007)
A draft of “Regulation of Review and Authorization of Biological Products”(Jul, 2009)
law on human tissues (19th March 2010), Ministry of Human Welfare (MHW)
Enforcement regulations (Oct 2004), MHW
Guidelines for Management of cord blood bank (Act 2005), FDA.
TAIWAN Regulation of Organ Banks
Regulation of Human Biobanks
The regulation of prevention of infectious diseases
Guidelines of research usage of human biopsy, tissue and fluid
Guidelines of research ethics for human embryo and embryonic stem cells.
CHINA 人体器官移植条例Regulations on human organs transplantation (4–6–2007)
http://wsj.sh.gov.cn/website/b/28586.shtml
骨组织库管理Standard for human musculoskeletal tissue bank( 3–1–2011) 
眼库管理Standard for human eye tissue bank( 3–1–2011)
http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohzcfgs/s7850/201009/48944.htm
脐带血造血干细胞治疗技术管理规范Regulations on therapeutic technology of cord blood stem cells (11–13–
2009)
http://wsj.sh.gov.cn/website/b/48446.shtml
医疗技术临床应用管理办法Regulations on therapeutic technology for clinics (3–2–2009)
http://wsj.sh.gov.cn/website/b/43522.shtml
涉及人的生物医学研究伦理伦查伦法Ethical Guidelines on the use of human tissue in research (1–11–2007)
http://wsj.sh.gov.cn/website/b/28676.shtml
EU Commission Directive 2006/86/EC implementing Directive 2004/23/EC of the European Parliament 
and of the Council as regards traceability requirements, notification of serious adverse reactions and 
events and certain technical requirements for the coding, processing, preservation, storage and 
distribution of human tissues and cells. (October, 2006)
Commission Directive 2006/17/EC  
implementing Directive 2004/23/EC of the European Parliament and of the Council as regards 
certain technical requirements for the donation, procurement and testing of human tissues and 
cells. (February, 2006)
Directive 2004/23/EC  
of the European Parliament and of the Council of 31 March 2004 on setting standards of quality 
and safety for the donation, procurement, testing, processing, preservation, storage and 
distribution of human tissues and cells. (April, 2004)
European Parliament legislative resolution  
on the Council common position adopting a European Parliament and Council directive on setting 
standards of quality and safety for the donation, procurement, testing, processing, preservation, 
storage and distribution of human tissues and cells (10133/3/2003 - C5–0416/2003 - 
2002/0128(COD)) (December, 2003)
ISBER Best Practice for Repositories: Collection, Storage, Retrieval and Distribution of Biological Materials 
for Research (2012)
FACT Cellular Therapy Accreditation Manual (5th Edition, 2012)
AHCTA Position Paper: Towards Global Standard for Donation, Collection, Testing, Processing, Storage and 
Distribution of Allogeneic HSC and Related Cellular Therapies (2008)
ECVAM Guidance of Good Cell Culture Practice – A Report of the Second ECVAM Task Force on Good Cell 
Culture Practice (2005)
NCI – NIH-USA NCI Best Practice for Biospecimen Resources (2011)
ISSCR Guidelines for the Clinical Translation of Stem Cells (2008)
Guidelines for the Conduct of Human Embryonic Stem Cell Research (2006)
OECD Guidelines for Human Biobanks and Genetic Research Databases (HBGRDs) (2009)
OECD Best Practice Guidelines for Biological Resource Centers (2007)
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Appendix 6. An example of release criteria*: characterization data for information** and 
specifications for seed stocks of undifferentiated hPSC lines.
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Appendix 7. Examples of QA definitions used in GMP manufacture
The terminologies given here are purely examples drawn primarily from the FDA tissue banking regulation [108]. There are no wholly 
agreed terminologies for this area and it is therefore important to use the definitions of QA terms recommended in national guide-
lines. In some cases there are significant difference in the scope of a definition under different jurisdictions such as the definitions 
for serious adverse events in the EU and the USA. ICH definitions [109] is very similar to FDA Medwatch and is probably one of the 
best harmonized terminologies. The PAS terminology [2] provides the UK and EU definitions and the regulatory reference for QA 
terms in Europe is the European Tissues and Cells Directive.
QA DEFINITIONS
ACCEPTANCE CRITERIA: The specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with 
an associated sampling plan, that are necessary for making a decision to accept or reject a lot or batch of raw material, intermediate, packaging 
material, or product. This term can also be applied to validation.
ADVERSE EVENT: Any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and 
that does not necessarily have to have a causal relationship with this treatment.
ADVERSE REACTION: A noxious and unintended response to any human cells, tissues, and cellular and tissue-based products for which there is a 
reasonable possibility that the HCT/P caused the response.
ASEPTIC PROCESSING: The processing of cells/product by methods that avoid or minimize contamination with microorganisms from the 
environment, processing personnel and/or equipment. 
AUDIT: A review of procedures, records, personnel activities, reagents, materials, equipment and facilities to determine adherence to standards and 
regulations. 
BATCH: A batch, sometimes called lot, is defined as an entity, by either time or quantity or both, of a product that is intended to have a uniform 
character and quality. A batch must be produced within predefined and specified conditions following a defined manufacturing process.
BATCH MANUFACTURING RECORD (BMR): The necessary quality documentation for tracing the complete cycle of manufacture of a batch or 
lot.
BATCH RECORD REVIEW: The process of reviewing and approving all Product Manufacturing and control records is called the batch record 
review. This includes, but is not limited to, packaging and labeling. The batch record review is performed by the quality unit to determine compliance 
with all established approved written procedures before a batch is released. 
DISPOSITION: The destination of cells/product for research, transplantation or discard.
DISTRIBUTION: A process including the receipt of a request for, selection of, and inspection of cells/product, and their/its shipment for delivery to 
recipient. 
DOCUMENTATION: Any procedures, instructions, logbooks, records, raw data, manuals, and policies associated with the development, 
manufacture, testing, marketing and distribution of a product required demonstrating compliance with applicable worldwide regulatory 
requirements.
EQUIPMENT QUALIFICATION: Protocols to evaluate equipment performance following instillation and before use, to ensure normal function 
within required tolerance limits. 
FACILITIES: The facilities are used for the manufacturing of cell therapy products with predefined environmental control following the applicable 
standards of e.g., particulate and microbial contamination. The facilities should be constructed and used reducing the introduction, generation and 
retention of contaminants within the area.
IN-PROCESS CONTROL (IPC): Testing and activities performed during production to monitor and, if necessary, adjust the process to assure that 
the product conforms to its specifications.
INTERMEDIATE: An intermediate product e.g., cell line that must undergo further processing before it becomes a final product. 
LABEL: A written, printed or graphic indication affixed to a container/ package describing critical information about the cells/product. 
LOT: Cells/product derived from one donor, banked at one time using the same reagents and materials, and identified by a unique identification 
number. 
PROCEDURE: A series of ordered steps designed to achieve a specific outcome when followed. 
42 future science group
Supplement    International Stem Cell Banking Initiative (ISCBI)
Regen. Med. (2015) 10 (2)s
PROCESS VALIDATION: Establishing documented evidence that provides a high degree of assurance that a specific process will consistently produce 
a product meeting its pre-determined specifications and quality attributes.
QUALITY: The term quality is used as the totality of features and characteristics of a product that bears on its ability to satisfy stated or implied 
needs including the conformance to requirements to specifications.
QUALITY ASSURANCE: A formal methodology designed to provide adequate confidence that the entire production of a product will fulfil 
requirements for quality under a wide conditions of operation. Quality assurance includes formal review of care, problem identification, corrective 
actions to remedy any deficiencies and evaluation of actions taken. 
QUALITY ASSURANCE UNIT: Sets policies, procedures and specifications, audits, reviews, assesses and training including continuous evaluation of 
the adequacy and effectiveness of the overall quality program.
QUALITY CONTROL: A procedure or set of procedures intended to ensure that a manufactured product adheres to a defined set of quality criteria. 
QUALITY CONTROL UNIT: The function in the quality unit that is responsible for the ongoing control of product and environment quality. 
Therefore the quality control unit (QC) has the overall responsibility for acceptance or rejection of e.g., raw materials, cell lines/intermediate 
products/final products, packaging components.
IN-PROCESS CONTROLS (IPC), LABELLING AND INSPECTION: Assurance that supporting systems are being controlled and monitored.
QUALITY SYSTEM: Organizational structure, responsibilities, procedures, processes, and resources for implementing quality management. 
QUARANTINE: The storage of materials/cells/ product in an isolated area until deemed safe (cleared/approved) for use.
SERIOUS ADVERSE EVENT/REACTION (ICH DEFINITION: Topic E2A1): Is an untoward medical occurrence which is: fatal, life-threatening 
(risk of death at the time of the event), disabling, or incapacitating resulting in hospitalization, or medically significant congenital abnormalities.
SERIOUS ADVERSE EVENT (EU TCD): Any untoward occurrence associated with the procurement, testing, processing, storage and distribution of 
tissues and cells that might lead to the transmission of a communicable disease, to death or life-threatening, disabling or incapacitating conditions for 
patients or which might result in, or prolong, hospitalization or morbidity
SERIOUS ADVERSE REACTION (EU TCD): Unintended response, including a communicable disease, in the donor or in the recipient associated 
with the procurement or human application of tissues and cells that is fatal, life-threatening, disabling, incapacitating or which results in, or prolongs, 
hospitalization or morbidity.
SPECIFICATIONS: Used for the predefined written, chemical, physical, biological and environmental characteristics for testing a product or system. 
This includes, but is not limited to, starting materials, packaging materials, intermediate, bulk, or product.
STANDARD: An accepted or authoritatively established principle or practice for quality assurance (e.g., SOP).
STANDARD OPERATING PROCEDURE: A detailed description of a procedure or process for quality assurance.
TRACEABILITY: The ability to locate cells/product at any point/step during production, processing, testing, storage, distribution or disposition. 
VALIDATION: The procedure for establishing documented evidence that a specific system is constructed and operates according to a predetermined 
set of specifications and guidelines. Validation includes but is not limited to: equipment, computer systems, production processes, cleaning 
procedures, facilities, utilities as well as analytical methods. 
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Appendix 8: Preservation technologies and methods
 Mode of cryopreservation
Two approaches to cryopreservation have been applied to stem cells: vitrification and slow cooling [101]. Both of these are capable of 
ensuring high survival if appropriately applied.
 Vitrification
The vitrification method currently applied is a non-equilibrium approach relying on ultra-rapid cooling with low concentrations of 
CPA to achieve the ice-free vitreous state. This is a meta-stable state which is prone to de-vitrification (with the potential for subse-
quent damaging ice formation) if those conditions necessary to maintain the vitreous state (notably a stable low temperature) are not 
maintained (see storage and transportation).
The choice of container and the unit volume of material being cooled should be considered when vitrification methods are 
employed, since both these will affect the maximum attainable cooling and warming rate. The ultra-rapid cooling rates necessary 
to effect vitrification require both high surface to volume ratios (with regard to container geometry) and small volumes (of the order 
of microliters per unit sample). In preparing large banks of cells, consideration should be given to the practicality of this method for 
scale-up due to the need to preserve relatively small numbers of cells at one time.
Consideration should also be given to the use of open straws and Dewars containing non-sterile liquid nitrogen (LN
2
) into which 
the straws are plunged. Neither of these can be considered to be best practice both from a microbiological or regulatory perspective. 
Alternatives to the open straw method, such as closed straws and straw-in-straw methods, should be considered, but there may also 
be important logistical constraints (e.g., size of the bank, mode of transportation) which must be reconciled with the requirements 
of the preservation method. 
Other alternatives for ice-free preservation, such as equilibrium approaches utilizing high concentrations of CPA [99] and/or the 
addition of natural or synthetic ice blocking molecules coupled with slow cooling [110] have not as yet been applied to stem cells.
 Conventional slow cooling
During slow cooling, ice formation will occur within the system resulting in the concentration of solutes in the remaining liquid 
phase in which the cells reside. Damage results mainly from exposure to these high solute concentrations (so-called solution effects), 
but may also occur as a result of intracellular ice formation. Ice formation within cells is generally a consequence of rapid cooling, 
but may occur in tissues at slow cooling rates as a random event leading to ice propagation to surrounding cells. It should be noted 
that CPAs militate against damaging solution effects of slow cooling but not against damage caused by intracellular ice formation.
Conventional slow cooling methods are generally more amenable to the production of large banks of cells produced as ‘single’ cell 
suspensions. For stem cells cryopreserved as colony fragments, if slow cooling methods are to be applied, consideration should be given 
to methods to control ice nucleation such as the inclusion of ice nucleating agents or seeding samples at high sub-zero temperature [111].
 Methods of cooling
The high cooling rates required for vitrification are generally obtained by direct immersion of the sample into a cryogen, usually 
liquid nitrogen. Slow cooling can be effected by either controlled rate cooling or the use of passive cooling devices. In both cases, 
consideration must be given to issues of sample contamination and contamination of the cleanroom as well as those of reproduc-
ibility and validation (see validation).
Controlled rate freezers (CRFs) in which the chamber containing the product is cooled by the injection of LN
2
 will generally be 
located outside the cleanroom environment unless the resulting nitrogen vapour can be ported to the outside of the cleanroom and 
the chamber can be effectively sterilized between cooling cycles. If such devices are used, outside the production area, consideration 
should be given to the method by which cells are moved to the CRF, to ensure that CPA exposure time/temperature does not com-
promise cell survival or lead to contamination.
Liquid nitrogen-free, CRFs, such as those employing the Stirling Cycle principle, may provide an alternative [112,113]. While such 
equipment provides a clean room-compatible solution for controlled rate freezing, they should be assessed for their ability to provide 
the required cooling rates, unit volumes and bank sizes appropriate to the cell lines being banked.
The end point temperature at which cells are transferred from the CRF to low-temperature storage should be set at a sufficiently 
low temperature to ensure that during handling and transfer to permanent storage any rise in temperature of the samples does not 
expose the cells to damaging sub-zero temperatures (above approximately -70°C for frozen cells and above the glass transition tem-
perature for vitrified material).
Passive cooling devices are generally placed inside a mechanical freezer to equilibrate. A uniform and reproducible cooling rate can be 
obtained if there is careful control of the sub-zero environment. A sub-zero temperature of at least -70°C should be employed in order to 
limit the cells exposure to the most damaging sub-zero temperatures (between the equilibrium freezing point and ~ -40 to 60°C) and 
assist in providing a relatively linear cooling rate over this temperature range. Consideration should be given to temperature logging of a 
control sample for QC purposes, the use of a designated freezer and procedures to control access to this freezer during cryopreservation.
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Appendix 9. Review of teratoma methodologies used in different laboratories 
18 laboratories from 16 countries responded to a set of questions (see table) on the teratoma assays they used for evaluation of hESC 
lines. Methodologies used for teratoma assays showed little concordance for strain of mouse, site of injection, number of cells/volume, 
end point, inspection for metastasis and processing and analysis of tumors (data obtained by S Oh and L Healy of ISCBI).
Method component Details requested Range of methods reported
Preparation of hPSCs Culture method used prior to harvesting Feeder and feeder-free cultures used (some labs used both 
methods).
Harvest method used 4 methods used (TrypLE, trypsin, collagenase, mechanical)
Post-harvest processing before inoculation 3 methods used (cell centrifuged and resuspended, cells 
washed in growth medium or PBS and resuspended in the 
same, cells resuspended in medium with MatrigelTM)
 Cells inoculated Number and viability of cells inoculated Range of methods based on cell number (1000 -10,000,000), 
cell viability (range 80–95%), injection volume 20–150ul, and 
no determination of cell number or viability.
Site of inoculation Anatomical site and means of administration 
(e.g. syringe, surgical incision with cells on a 
substrate)?
4 different sites used (legs intramuscular (both sides), Kidney 
capsule, intra-testicular, subcutaneously head and neck and 
flank)
Test animal Strain of mouse used Seven different strains of mouse used (Nude Balb/c, SCID 
undefined, Nude/nude, SCID/Beige, SCID c gamma c -/-, 
SCID undefined, NOD/SCID, NOD/MrkBomTac-Prkdc SCID).
Frequency and natural onset of spontaneous 
tumors in the mouse strain
None identified or ‘low’
Age of animals used 2 age ranges used (7–8 weeks (majority) or 5–8 months)
Replicates of test No. of animals used for each test Ranged from 1–4 per cell line (3/cell line (majority), 1/cell line 
with 2–4 injection sites, 4/cell line)
Observation of animals Typical number of weeks post inoculation at 
which mice are sacrificed
4–12 weeks
Is there a maximum end point for incubation 
or are mice kept until natural death?
3 different limits used (2–4 months, tumor growth allowed to 
reach 1–1.5 cm or tumor growth allowed to reach 2 g)
Tumor incidence Frequency of mice developing tumors per 
experiment
Ranged from none-100% with an equal number of 
participants reporting incidence of tumors in mice at 
30–50% and 80–100%.
Method of tumor location Palpation and observation
Numbers of tumors expected per mouse 1–2 tumors per site
Frequency of metastasis Majority of participants reported metastases 
Tumor preparation Point at which palpable tumors are recovered 5–12 weeks or maximum size of 0.5–1.5 cm or maximum 
weight of 2 g
Processing of tumor Tumors fixed by alternative methods (paraformaldehyde or 
formalin, paraffin, cryosections) depending on post-fixation 
testing including 3 different techniques (histology [H&E, PAS 
etc], immune-staining or PCR).
Evaluation and reporting of 
tumors
Minimum criteria (in terms of histological 
data) to establish a cell line is ‘pluripotent’
Evidence of 3 germ layers
Are results from more than one mouse used 
in combination?
50% responded ‘no’, 50% responded ‘yes’ if using the same 
cell line
Variation in results observed between cell 
lines
Of those responding 50% reported no variation and 50% did 
see a significant variation
